GUIDANCE ON A STRATEGY FOR GENOTOXICITY TESTING OF CHEMICAL SUBSTANCES

CONTENTS

<table>
<thead>
<tr>
<th>PARAGRAPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Preface</td>
</tr>
<tr>
<td>II. Introduction</td>
</tr>
<tr>
<td>III. Significance of Chemical Induced Mutation for Human Health</td>
</tr>
<tr>
<td>IV. General Principles of Testing Strategy</td>
</tr>
<tr>
<td>V. Genotoxicity Testing Strategy</td>
</tr>
</tbody>
</table>

Stage 0: Preliminary Considerations Prior to Genotoxicity Testing (Figure 1)

<table>
<thead>
<tr>
<th>PARAGRAPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physico-chemical and Toxicological Properties</td>
</tr>
<tr>
<td>Structure Activity Relationships</td>
</tr>
<tr>
<td>Screening Tests</td>
</tr>
</tbody>
</table>

Stage 1: *In Vitro* Genotoxicity Testing (Figure 2)

<table>
<thead>
<tr>
<th>PARAGRAPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview of Strategy</td>
</tr>
<tr>
<td>Discussion of Stage 1 Tests - General aspects</td>
</tr>
<tr>
<td>Discussion of Stage 1 Tests - Core tests</td>
</tr>
<tr>
<td><em>In Vitro</em> Bacterial Tests for Gene Mutation</td>
</tr>
<tr>
<td><em>In Vitro</em> Mammalian Cell Micronucleus Test for Clastogenicity and Aneuploidy (MNvit)</td>
</tr>
<tr>
<td>Discussion of Stage 1 Tests - Non Core tests</td>
</tr>
<tr>
<td><em>In Vitro</em> Chromosomal Aberration Assay in Mammalian Cells (Metaphase Analysis) for Clastogenicity and Aneuploidy</td>
</tr>
<tr>
<td><em>In Vitro</em> Mouse Lymphoma Assay for Gene Mutation and Clastogenicity</td>
</tr>
<tr>
<td><em>In Vitro</em> CHO/HPRT assay for Gene Mutation</td>
</tr>
<tr>
<td><em>In Vitro</em> Assays using Human Reconstructed Skin</td>
</tr>
<tr>
<td><em>In Vitro</em> Alkaline Comet Assay for DNA Damage</td>
</tr>
</tbody>
</table>

Summary Stage 1: (*In Vitro* Genotoxicity Testing) | 60 |

Stage 2: *In Vivo* Genotoxicity Tests (Figure 3)

<table>
<thead>
<tr>
<th>PARAGRAPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview of Strategy</td>
</tr>
<tr>
<td>Discussion Stage 2-Initial Testing Strategy-General Aspects</td>
</tr>
<tr>
<td>Discussion Stage 2-Recommended Core <em>In Vivo</em> Genotoxicity Tests</td>
</tr>
<tr>
<td>Rodent Micronucleus and Chromosome Aberration Assays for Clastogenicity and Aneuploidy</td>
</tr>
<tr>
<td>Transgenic Rodent Mutation (TGR) for Gene Mutation</td>
</tr>
<tr>
<td>Rodent Comet Assay for DNA Damage</td>
</tr>
<tr>
<td>Non-Core <em>In Vivo</em> Test-Rat Liver UDS Assay for DNA Damage</td>
</tr>
<tr>
<td>Discussion Stage 2-Supplementary Tests</td>
</tr>
</tbody>
</table>

Summary Stage 2: (*In Vivo* Genotoxicity Testing) | 81-82 |

VI: Possible Future Developments | 83 |

Annex 1: Sensitivity and Specificity Data Considered by COM | 84 |

Annex 2: Tabulation of Genotoxicity Tests in Stages 1 and 2 and Mutagenicity and Genotoxicity End Points Detected |

Annex 3: Rationale for Selection of Ames Test and *In Vitro* Micronucleus Assays as the Two Principal *In Vitro* Tests
GUIDANCE ON A STRATEGY FOR GENOTOXICITY TESTING
OF CHEMICAL SUBSTANCES

Executive Summary

The Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment (COM) has a remit to provide UK Government Departments and Agencies with advice on the most suitable approaches to testing chemical substances for genotoxicity. The COM published guidance in 1981, 1989 and again in 2000. This document, incorporating some significant changes, reports on the COM views regarding the most appropriate strategy for genotoxicity testing reached in 2011.

The COM recommends a staged approach to testing:

**Stage 0** consists of preliminary considerations which include physico-chemical properties of the test chemical substance, Structure Activity Relationships (SAR), and information from screening tests. However, data from SAR and screening tests should not overrule test data from adequately designed and conducted genotoxicity tests.

**Stage 1** consists of *in vitro* genotoxicity tests. The COM recommends a core-test battery of the Ames test combined with the *in vitro* micronucleus test. This combination provides information on three types of genetic damage for which data are required (namely, gene mutation, chromosomal damage and aneuploidy) and gives appropriate sensitivity to detect chemical mutagens. There is no need to independently replicate adequately designed and conducted core *in vitro* tests which are either clearly negative or clearly positive. The strategy document also considers the value which can be attributed to a number of non-core *in vitro* tests.

**Stage 2** consists of *in vivo* genotoxicity tests. A case-by-case strategy should be developed to answer one or more of the following specific queries;

1) Investigation of mutagenic end point(s) identified in Stage 1,
2) Investigation of genotoxicity in *tumour* target tissue(s),
3) Investigation of potential for germ cell genotoxicity,
4) Investigation of *in vivo* mutagenicity for chemicals, which were negative in Stage 1 but where there is high or moderate and prolonged exposure,
5) Investigation of genotoxicity in site of contact tissues.
The core tests in Stage 2 are the rodent micronucleus/chromosome aberration assays for aneuploidy and clastogenicity, the transgenic rodent gene mutation assay and the rodent Comet assay for DNA damage.

Usually negative results obtained in a carefully selected *in vivo* test (possibly studying more than one endpoint and tissue) will be sufficient to address positive results found *in vitro*. However, a further test(s) may be needed if some of the genotoxic effects seen in Stage 1 *in vitro* tests had not been adequately studied *in vivo* (e.g. the chemical affects multiple mutagenic end-points), or other aspects of the genotoxic potential of the chemical had not been fully resolved (e.g. in the case where an investigation of heritable effects was required). The strategy document also considers the value which can be attributed to a number of non-core *in vivo* tests. In most instances information from core *in vivo* tests is sufficient to evaluate the *in vivo* mutagenicity of chemical substances. A supplementary *in vivo* test strategy can provide additional information on a case-by-case basis, to investigate aspects such as further characterisation of germ cell genotoxicity, and DNA adduct data which can provide information to elucidate the mode of genotoxic action of carcinogenic chemicals.

It is acknowledged that the field of genotoxicology and genotoxicity testing is rapidly developing. A short overview of possible future developments and techniques such as toxicogenomics is provided.
I. Preface

1. The Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment (COM) is an independent expert advisory committee whose members are appointed by the Chief Medical Officer for England and the Chair of the Food Standards Agency (FSA) following an appointments exercise involving public advertisement. Members serve in their own capacity as independent experts and observe a published code of practice including principles relating to the declaration of possible conflicting interests.

2. The remit of the COM is to advise all U.K. government departments and agencies with an interest in the safety of chemicals across various sectors on the human health aspects of the mutagenicity and genotoxicity of chemicals. (These terms are defined for the purposes of this guidance document in paragraphs 7-8 below.) The Secretariat is provided by the Health Protection Agency (HPA), who lead, and the FSA. Other government departments with an interest provide assessors to the COM; these are specifically from the Department of Health (DH), the Department of Environment, Food and Rural Affairs (Defra), the Chemicals Regulation Directorate (CRD) of the Health and Safety Executive (HSE) (responsible for legislation regulating chemicals, pesticides, biocides and detergents), the Environment Agency, the Veterinary Medicines Directorate (VMD: a Defra agency responsible for the licensing of veterinary drugs) and the Medicines and Healthcare products Regulatory Agency (MHRA; a DH agency responsible for the licensing of human medicines). In addition there are assessors from the Scottish Government, the Welsh Assembly Government and the Northern Ireland Assembly.

3. The role of the COM is advisory. It has no regulatory status, although its advice may be provided to a body that does have such a role (e.g. HSE CRD for occupational aspects and for pesticides etc). Its remit is to advise on the human health aspects of mutagenicity and genotoxicity of chemicals, and this may involve advice on a specific chemical, and also on testing strategies and research. This guidance document focuses on testing strategies for chemical substances for which there are no available genotoxicity data. Separate guidance on a strategy for the genotoxicity testing and mutagenic hazard assessment of chemicals with inadequate genotoxicity data is in preparation. Throughout this guidance the COM has referred to the genotoxicity testing of substance(s). In this document the term test substance refers to a specified chemical or material including any additive necessary to preserve its stability
and any impurity deriving from the process used. However the COM usually provides advice on a specific chemical substance which can be equated to a single chemical or compound or pure substance. http://www.hse.gov.uk/reach/definitions.htm#substance. The COM also has a general remit to advise on important general principles or new scientific discoveries in connection with potential mutagenic and genotoxic hazards (inherent properties of chemicals) or risk (the likelihood of mutagenic or genotoxic effects occurring after a given exposure to a chemical) and to present recommendations for genotoxicity testing. In practice the bulk of the work of the COM relates to assessing genotoxicity tests and providing advice on the mutagenic hazard of chemicals.

4. In the context of testing strategies, the COM first published guidelines for the testing of chemicals for mutagenicity in 1981, and these were revised in 1989 (DOH, 1989). These provided guidance to the relevant government departments and agencies on best practice for testing at those times. The need for guidance to be periodically updated, to reflect advances in development and validation of methods, was recognised and revised guidance was published in 2000 (DOH, 2000). This new guidance continues this updating process. The strategy outlined in this guidance is considered to be the most scientifically appropriate given available methods and recognises the need to avoid the use of live animals where practical and where validated alternative methods are available. It is recognised that, as with the earlier published COM guidance, it may be some time before this strategy is reflected in guidelines used by UK regulatory authorities.

5. The COM believes that the approach outlined presents an updated overview of the core principles of genotoxicity testing and will remain valid for several years. It is acknowledged that existing national or international testing strategies will be at different stages of review and hence inconsistencies are expected. The COM guidance is not intended to supersede or replace existing national or international sector-specific genotoxicity testing strategies (e.g. those recommended for pharmaceuticals by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html and for chemicals assessed under the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation (EC1906/2006)
II. Introduction

6. The COM last published guidance on a strategy for the testing of chemicals for mutagenic potential in 2000 (DOH, 2000). The rationale developed by COM in 2000, particularly in relation to the testing of all potential mutagenic endpoints, has also been adopted by the International Workshops on Genotoxicity Testing (IWGT) (Muller et al., 2003). Since 2000 there has been development of new approaches to identifying genotoxic hazards \textit{in vitro} including new approaches to identify misleading positive results and evaluate target organ genotoxicity \textit{in vivo}. There is also a need to develop a testing strategy which can encompass chemicals such as cosmetics where no animal tests are permitted under EU law. It is the objective of this paper to set out a scientifically valid testing strategy comprising those methods which the COM believe to be the most informative with regards to the detection of genotoxic hazard and (when possible) are well validated. There is no discussion of methods which experience has shown to have no place in the recommended genotoxicity testing strategy. Details of methodologies are not given since they are provided in the Organisation for Economic Cooperation and Development (OECD) test guidelines, the EU Test Methods Regulation (EC 440/2008) and the International Workshops on Genotoxicity Testing (IWGT) guidance.

7. The \textit{genome} can be damaged in a variety of ways either spontaneously or from exposure to genotoxic agents. The term "mutagenic" refers to the ability of a substance to induce a permanent change in the amount or structure of the genetic material of an organism, which may result in a heritable change in the characteristics of the organism. Chemicals inducing \textit{mutations} are referred to as mutagens (they are mutagenic). These alterations may involve individual genes, blocks of genes, or whole chromosomes. Mutations involving single genes may be a consequence of effects on single DNA bases (point mutations) or of larger changes, including deletions and rearrangements of DNA. The potential to induce mutation is measured in test systems that detect a broader range of genetic changes than simply mutation
they measure genotoxicity. Mutagenicity is accepted as a key event in carcinogenicity.

8. Genotoxicity refers to interaction with, or damage to, DNA and/or other cellular components which regulate the fidelity of the genome. It is a broad term that, as well as mutation (see paragraph 7) includes damage to DNA such as the production of DNA adducts, by the chemical itself or its metabolites. Cells have the capacity to protect themselves from such potentially lethal or mutagenic genotoxic effects by many repair processes and therefore many genotoxic events do not become evident as mutations. However, the capacity to damage the genome (genotoxicity) is an indicator of potential mutagenicity. Thus, some methods that measure genotoxicity may not provide direct evidence of heritable mutation.

9. The objective of genotoxicity testing is to exclude or identify potential mutagenic hazards to humans, and, for those substances that are positive, to aid in the elucidation of the mode of genotoxic action (MoGA). This guidance therefore presents a strategy for genotoxicity testing since this term encompasses all the assays included in the strategy. Consequently, it is important to generate information on three types of genetic damage, namely gene mutation, changes to chromosome structure (i.e. clastogenicity) and number (i.e. aneuploidy), to provide comprehensive coverage of the mutagenic potential of a chemical.

10. The COM reaffirms its view, published in 1989 and 2000, that there is currently no single validated assay that can provide comprehensive information on all three types of genetic damage and thus it is necessary to subject a given test substance to several different assays. The range of assays discussed in this document include those using prokaryotes (bacteria) and mammalian cells in vitro, and whole mammals, where effects in a wide range of target organs including germ cells can be measured. Assays may be classified on the basis of genetic end-points (e.g. gene mutation, clastogenicity, aneugenicity and tests for DNA damage) or by consideration of the different phylogenetic levels (e.g. bacteria, and mammalian cell) represented and also in mammals by the tissues or target organs studied.

III Significance of Chemical-Induced Mutation for Human Health

11. A mutation in the germ cells of sexually-reproducing organisms may be transmitted to the offspring, whereas a mutation that occurs in somatic cells
may be transferred only to descendant daughter cells. Mutagenic chemicals may present a hazard to health since exposure to a mutagen carries the risk of inducing germ-line mutations, with the possibility of inherited disorders, and the risk of somatic mutations including those leading to cancer.

12. A separate statement discussing the significance of chemical-induced mutation to human health is in preparation.

IV. General Principles of Testing Strategy

13. The COM recommends a two-stage genotoxicity testing strategy (Stages 1 and 2) for the detection of the mutagenic hazard of chemicals which can be supported by appropriate preliminary screening tests and/or in silico data (Stage 0). Initial testing for mutagenic potential in Stage 1 is based upon two core in vitro tests that are chosen to provide information on gene mutation, clastogenicity and aneuploidy, with case-by-case additional testing and investigation depending on the results of these initial genotoxicity tests. All in vitro tests should be designed to provide the best chance of detecting potential activity, with respect to (a) the exogenous metabolic activation system (S9 - see glossary); (b) the ability of the compound or its metabolite(s) to reach the target DNA and/or targets such as the cell division apparatus, and; (c) the ability of the genetic test system to detect the given type of genotoxic event. Where international guidance is available, the assays should be carried out to conform to those internationally recognised protocols e.g. as published by the OECD, the IWGT and in the EU test methods Regulation (EC 440/2008). The same approach to testing can be used for chemical substances where in vivo genotoxicity testing is not permitted (e.g. cosmetics). Investigations regarding MoGA are important to derive conclusions on biological relevance of genotoxicity test results, to aid in overall risk assessment, and to inform on the strategy for in vivo tests. This is of particular importance for those chemicals where no in vivo genotoxicity testing is permitted.

14. For most chemicals, results from the two Stage 1 core tests should be sufficient to reach a conclusion on the presence or absence of mutagenic potential. However, in some instances, even when Stage 1 tests are negative, regulatory authorities may require consideration of the need for in vivo Stage 2 testing particularly where exposure is considered to be high, or moderate and prolonged (e.g. most human medicines), or where there is a chemical class precedent of positive in vivo genotoxicity data. Guidance on
the level of exposure which equates to high, moderate or prolonged is beyond the remit of the COM.

15. Stage 2 consists of a number of *in vivo* tests designed to investigate whether *in vitro* genotoxic activity including specific mutagenic end-points identified by *in vitro* tests can be expressed in the whole animal. This may also include assays for specific target organs (e.g. rodent tumours detected in carcinogenicity bioassays) or in germ cells. Few chemicals are active only *in vivo* and in such cases this may be due to a number of factors such as metabolic differences, the influence of gut flora, higher exposures *in vivo* compared to *in vitro* and pharmacological effects (e.g. folate depletion or receptor kinase inhibition) (Tweets et al, 2007b).

There is currently no single *in vivo* test which can assay all three types of genetic damage (Thybaud et al., 2007) and thus a strategy for Stage 2 has to be designed based on the nature of genotoxic effects identified in Stage 1 and the possibility that genotoxic activity will only be expressed *in vivo* as discussed above. However consideration should be given to the possibility of evaluating different genotoxicity endpoints in a single set of test animals.

16. There should be a clear strategy for planning tests within each stage and for progressing from Stage 1 to Stage 2. Clear statements can be made regarding the initial *in vitro* tests to be used in Stage 1 as these methods have been well studied, whereas the strategy for Stage 2 is more complex and, if not a specific regulatory requirement, needs to be developed on a case-by-case basis.

17. Under the strategy recommended by COM, the use of animals in mutagenicity testing is primarily required when it is necessary to investigate whether genotoxic activity detected in Stage 1 *in vitro* is reproduced *in vivo*, to study target organ genotoxicity (for example involvement of genotoxicity in rodent tumours (Kirkland et al., 2007a) and to evaluate the potential for heritable mutagenic effects. Genotoxicity testing using animals should be carried out when there is no suitable alternative, and the minimum number of animals should be used, consistent with obtaining valid results. If feasible, studies can be conducted as an adjunct to single or repeat dose toxicity studies. The COM supports current and future developments to replace, refine or reduce the need for *in vivo* genotoxicity testing.
V Genotoxicity Testing Strategy

18. The COM guidance provides a strategy for testing chemical substances where no genotoxicity data are available. Test substances may also contain impurities at varying levels which may exhibit genotoxic activity. Separate guidance on the genotoxicity assessment of impurities has been identified as a priority project during the COM horizon scanning exercise in 2010 (see minutes of COM meeting of October 2010 http://www.iacom.org.uk/meetings/index.htm), and is currently the subject of an ICH expert working group.


The strategy recommended in the following sections is concerned with testing for genotoxic activity of chemical substances and does not specifically address complex mixtures of chemicals. Since the publication of the COM guidance in 2000, assessments of the performance of (Q)SAR approaches, screening tests and genotoxicity assays (both individually and in combinations) regarding the prediction of rodent carcinogenicity have been published (Kirkland et al., 2005a; Kirkland and Speit, 2008; Matthews et al., 2006a; Matthews et al., 2006b). Reference to these publications can provide an insight into the performance of the in vitro genotoxicity assays specifically in relation to the particular data sets analysed and the end points considered, predominantly rodent carcinogenicity but also in vivo genotoxicity (Kirkland et al., 2011). Relevant sensitivity and specificity data and assay performance assessments have been summarised in Annex 1, and are discussed further in Annex 3, for information and are cited where appropriate in the text below. Overall the older available data suggest that mammalian cell assays did not perform well at discriminating between rodent carcinogens and non-carcinogens. However, recent experience suggests that mammalian cell tests conducted and interpreted according to current recommendations perform more robustly (Fellows et al., 2011).

Stage 0: Preliminary Considerations Prior to Genotoxicity Testing (Figure 1)

19. The intrinsic chemical and toxicological properties of the test substance must be considered before devising the genotoxicity testing programme.
Physico-chemical and Toxicological Properties

20. The physico-chemical properties of the test substance (for example, pKa, partition coefficient, solubility, volatility and stability in, and potential reactions with, solvents/vehicles) and its purity can affect the ease of conduct and results of *in vitro* tests. For example, the tolerance of cells to acidic chemicals can be enhanced by neutralisation but this may affect the inherent reactivity of substances to DNA (Hiramoto et al., 1997). Potential reactions of the test substance with solvent /vehicle should also be considered (e.g. cisplatin reacts with DMSO) (Fischer et al., 2008). Alternatively, low solubility may limit the feasibility of undertaking some or all of the *in vitro* mutagenicity tests recommended in this strategy. The potential for auto-oxidation of the test chemical in the culture medium can also affect the outcome of *in vitro* genotoxicity tests (Long et al., 2007). It is noteworthy that the toxic properties of test substances, such as target organ effects, or irritancy/corrosivity in contact with skin or mucous membranes and their toxicokinetics and metabolism will influence the choice of route of administration and the highest dose level achievable in Stage 2 *in vivo* mutagenicity tests.

Structure Activity Relationships

21. Whether the test substance would be expected to have mutagenic potential may be assessed from its chemical structure, which may provide structural alerts for mutagenicity. A composite model structure was originally devised by Ashby and Tennant indicating substituent chemical groups or moieties associated with DNA-reactivity (Ashby and Paton, 1993). A number of freely available and commercial systems to investigate structure activity relationships (SAR) for mutagenicity have been developed and evaluated since 2000 (Benigni and Bossa, 2008; Benigni et al., 2007; Cariello et al., 2002; Contrera et al., 2005; Snyder and Smith, 2005; Zeiger et al., 1996). Further information on various models is provided in Annex 1. The OECD (OECD, 2004) and the European Commission (Joint Research Centre) have published principles for the validation of (Q)SAR ((Quantitative) Structure Activity Relationships) (Worth et al., 2005, Benigni and Bossa, 2008). (Q)SAR assessment of the *in vitro* mutagenicity in bacteria has been attained by two types of approach; statistical analyses of structure and mutagenic activity
and/or (Q)SAR models using programmed rules for prediction of mutagenic activity based on the available knowledge and expert judgement.

22. Such (Q)SAR systems can be useful when a large number of chemicals require assessment and prioritisation for genotoxicity testing or in instances where a rapid assessment of a chemical is required and there are no genotoxicity test data available. Each (Q)SAR system has a defined domain of applicability which is determined by the structural descriptor factors, modes/mechanism of mutagenicity, and metabolic aspects included within the system. In addition in silico approaches can aid in the interpretation of Stage 1 in vitro genotoxicity test results (Dearfield et al., 2011). The available systems perform well for prediction of bacterial mutagenicity (i.e. for chemical structures within the domain of applicability of the model under consideration) (see Annex 1). However, lower sensitivities and specificities have been reported for a number of systems when used for prediction of results from in vitro cytogenetics or the mouse lymphoma assay (e.g. using MCASE and MDL-QSAR) (Contrera et al., 2008). One factor in the lower predictive capability of (Q)SAR systems for mammalian cell genotoxicity assays is inadequate coverage of non-covalent DNA interactions and non-DNA targets associated with cell division (Grant et al., 2000; Snyder and Smith, 2005). It has also been proposed that (Q)SAR assessments can aid in the interpretation of the relevance of in vitro genotoxicity assays through prediction of biotransformation (Combes et al., 2007). Other systems combining metabolic simulation with structure toxicity rules have been developed (e.g. TIMES; tissue metabolic simulator) but are at a relatively early stage of validation (Mekenyan et al., 2004; Serafimova et al., 2007). Lhasa Ltd has developed a computer programme (METEOR), which has the facility to integrate prediction of metabolism with (Q)SAR approaches for genotoxicity. (https://www.lhasalimited.org/meteor/). An authoritative and comprehensive evaluation of the different (Q)SAR approaches to the identification of genotoxic potential has been prepared for the European Food Safety Authority (EFSA) by the Computational Toxicology group, Institute for Health & Consumer Protection, European Commission-Joint Research Centre (JRC), Ispra, Italy (http://www.efsa.europa.eu/en/scdocs/scdoc/50e.htm). A compilation of structural alerts for prediction of the rodent in vivo micronucleus assay has recently been published. The authors advocate that
the derived rules can be used for preliminary identification of in vivo mutagens
(Benigni et al., 2010).

23. Overall, (Q)SAR approaches for the prediction of genotoxic activity can be a
valuable tool to aid in the high throughput screening of compounds, the
provision of assessments for chemicals for which no genotoxicity test data are
available and also prioritisation for genotoxicity testing. (Q)SAR can also aid
in the interpretation of genetic toxicology tests, although such predictions
cannot replace the need to undertake the in vitro and in vivo genotoxicity tests
required to derive conclusions on mutagenic hazard. However, expert
judgement is needed when reaching conclusions on mutagenic hazard on the
basis of (Q)SAR information alone. In reaching conclusions, data from well
created in vitro or in vivo genotoxicity tests should be attributed a much
higher weight of evidence than (Q)SAR predictions, although all information
should be assessed on a case-by-case basis.

Screening Tests

24. There are a number of current initiatives which attempt to combine data
mining in silico approaches with high throughput tests to develop approaches
to screening large numbers of novel chemicals (Benfenati et al., 2009.). In
this guidance, genotoxicity screening tests refers to high throughput tests
which have been designed to be rapid, economical, reproducible, require only
small amounts of test substances (typically below 50 mg) and have a high
concordance with comparator genotoxicity end points in genotoxicity tests.
(These tests are also often referred to as pre-screening tests.) High
throughput bacterial tests have been developed using combinations of
Salmonella tester strains (Ames II™), primary DNA damage (umu assay),
mutations in ampicillinase gene (MutaGen assay), bioluminescence or 5-
fluorouracil resistance (Ackerman et al., 2009; Aubrecht et al., 2007; Kamber
et al., 2009 ; Miller et al., 2005 ; Reifferscheid et al., 2005). Other screening
systems cited in the literature include DNA repair activity in yeast cells
(Westerink et al., 2009). One research group has proposed a combination of
two commercial screening assays (Vitotox™ for bacterial mutagenicity and
RadarScreen yeast screen for clastogenicity) for rapid screening of
compounds. (Westerink et al., 2009).

25. A number of genotoxicity screening tests using in vitro systems have been
proposed, including alkaline elution using rat hepatocytes (Gealy et al., 2007),
the detection of DNA damage (via p53 or GADD45a activation, GreenScreen) in cell lines (Knight et al., 2009) and differential survival in DNA repair proficient and deficient cell lines (Helleday et al., 2001). A screening test for genotoxicity using HepG2 cells (metabolically competent with wild type p53 genotype) based on four different luciferase-reporter assays has been published. The authors claim, based on a small dataset, a high sensitivity for identification of genotoxicity when used in combination with the commercially available systems (Vitotox™ and RadarScreen) (Westerink et al., 2010). None of these genotoxicity screening tests have reached the stage of development where they could routinely be used to replace data generated from in vitro genotoxicity testing. The predominant use of high throughput screening tests is as an aid in prioritisation of compounds for development undertaken by industry. The COM reviewed the GADD45a-GFP assay and it was agreed that currently, it is most suited as part of a battery of high throughput screening (COM minutes March 2010, http://www.iacom.org.uk/meetings/index.htm).

26. High throughput genotoxicity screening tests can be used in a tiered approach with in vitro genotoxicity tests to aid in the selection of chemicals for development. It has been suggested that greater validation and acceptance by regulatory authorities of these tests could lead to the replacement of existing genotoxicity testing strategies with a combination of high throughput screening tests (Custer and Sweder, 2008).

Stage 1: In Vitro Genotoxicity Testing (Figure 2)

Overview of strategy

27. The COM concluded in 1989 and 2000 that it was appropriate to concentrate on a relatively small number of assays, using validated, sensitive methods particularly chosen to avoid misleading negative results. Two important parts of the revised Stage 1 strategy include using appropriate tests to gain an insight into the nature of the genotoxic effects of a test substance and also to avoid misleading positive results. Misleading positive results have been reported for certain mammalian cell assays (Fowler et al., 2010; Pfuhler et al., 2009; Kirkland et al., 2007a) particularly when multiple test systems were used.
As outlined above in paragraphs 13 and 14, Stage 1 involves tests for genotoxic activity using in vitro methods and comprises a two test core system (namely an Ames test and in vitro micronucleus test (MNvit)) with the objective of assessing mutagenic potential by investigating three different end points (gene mutation, structural chromosomal damage and changes in chromosome number). The rationale for this test strategy is given in Annex 3. A clear positive result in either of these two core tests is sufficient to define the chemical as an in vitro mutagen, although further in vitro and/or in vivo testing may be undertaken to understand the relevance of the positive results. The Committee considers that this revised strategy allows for efficient identification of all mutagenic-end points but, by reducing the number of mammalian cell tests from that recommended by COM in 2000, and following improved methodologies, the risk of misleading positive results is decreased.

Additional investigations of chemicals which give positive or repeated equivocal results in Stage 1 tests can include an assessment of mode(s) of in vitro genotoxic action. There are a number of reasons (discussed in paragraphs 34-37) why positive results in in vitro genotoxicity tests might occur by mode(s) of action not relevant to human health hazard assessment. Such MoGA evaluation in vitro is particularly relevant for those chemicals (e.g. cosmetics) where there is a regulatory constraint which precludes the use of in vivo genotoxicity assays in the testing strategy. The COM does not recommend the use of in vitro genotoxicity assays that have not been considered in detail in this guidance such as assays for sister chromatid exchange, the in vitro UDS assay or tests using fungi. A table of mutagenic endpoints detected by each genotoxicity assay cited in Stage 1 of this strategy is given in Annex 2.

For chemicals which give equivocal results or repeated small positive effects, it is important to consider evidence of reproducibility in the same assay or in different assays detecting similar effects, and the magnitude of the induced genotoxic effect in relation to historical negative control data, and then consider whether further in vitro genotoxicity testing is needed (Kirkland et al., 2007a; Hayashi et al., 2011). Further consideration of SAR data for these chemicals may also give valuable information (Dearfield et al., 2011).

If clear negative results are obtained in both core in vitro tests undertaken, it can generally be concluded that the chemical has no mutagenic activity. However, there are some occasions when additional in vitro and/or in vivo
genotoxicity testing may be undertaken for chemicals giving a negative response in the two *in vitro* core genotoxicity tests. For example, situations where *tumours* are found in rodents, where the *in vitro* metabolic activation systems are not optimal or where there are human-specific metabolites, may need to be subject to further genotoxicity assessment. A further testing strategy would have to be designed on a case-by-case basis (Muller et al., 2003; Kirkland et al., 2007a). An IWGT working group has published guidance on this topic (Kasper et al., 2007). An important part of any additional *in vitro* strategy should be consideration of the appropriate exogenous metabolic activation system (including alternative sources of S9 or other metabolic systems including genetically engineered cell lines, see paragraph 36)(Ku et al., 2007b). Further information on *in vivo* genotoxicity testing of such test substances is provided in Stage 2 of this strategy.

32. Information from other combinations of genotoxicity tests which may include one or more non-core tests outlined below in paragraphs 54-59 may also give adequate data on all three end-points on a case-by-case basis. *In vitro* genotoxicity tests using human reconstructed skin may provide useful information on *in vitro* mutagenic hazard in circumstances where *in vivo* testing is not permitted, or when extensive dermal exposure is anticipated (e.g. cosmetic ingredients).

33. The full Stage 1 strategy should be performed and the results of studies evaluated before a decision is made on whether to proceed to Stage 2 testing or whether a conclusion on mutagenic hazard can be derived for test substances where no *in vivo* genotoxicity testing is permitted. An outline of Stage 0 and Stage 1 (*in vitro* genotoxicity testing) is given in Figure 2 and a description of the assays recommended is provided in the following paragraphs.

**Discussion of Stage 1 Tests- General Aspects**

34. The conduct of genotoxicity assays has improved over time and the overall sensitivity of *in vitro* testing strategies regarding prediction of rodent carcinogens is very high (Kirkland et al., 2005a; Kirkland et al., 2007c). Proposals have been published for genotoxicity testing advocating a single *in vitro* genotoxicity test (Ku et al., 2007a) or a complex approach involving up to six *in vitro* genotoxicity tests (SCCNFP/0720/03) and critically evaluated by Kirkland et al (Kirkland et al., 2005b). Neither of these approaches is
considered preferable to the proposed Stage 1 core testing. Although the sensitivity (producing positive results with carcinogens) for rodent carcinogenicity of a battery of Stage 1 tests was very high, the specificity (producing negative results with non-carcinogens) was poor (Kirkland et al., 2005; Kirkland et al., 2007a,b). Possible reasons for the poor specificity have been discussed by various working groups e.g., see (Kirkland et al., 2007a). A comprehensive review of the performance of Stage 1 genotoxicity assays for prediction of rodent carcinogenicity reported positive results in one or more in vitro tests for a substantial number of rodent non-carcinogens (as assessed by the Carcinogenic Potency Database (CPDB), National Toxicology Program (NTP), and the International Agency for Research on Cancer (IARC)). Thus the specificity (i.e. correct identification of rodent non-carcinogens) was considered to be reasonable for the Ames test (74%) but poor for the mammalian cell assays (below 45%) particularly when multiple assays were performed (Elespuru et al., 2009; Kirkland et al., 2005a). Many reasons for low specificity have been proposed, particularly for mammalian cells; for example, the use of high-concentrations, cytotoxicity, prolonged exposure, overloading defence mechanisms, lack of detoxification capacity. The influence of such confounding effects leading to indirect mechanisms of genotoxicity, has been widely recognised (Kirsch-Volders et al., 2003b; Müller and Kasper, 2000; Pratt and Barron, 2003)

35. A more recent analysis on the sensitivity of a combination of Ames test and MNvit test to detect rodent carcinogens and in vivo genotoxicants is summarised and discussed in Annex 3 Table 1, and published in Kirkland et al (Kirkland et al., 2011). It is difficult to draw precise conclusions from the available sensitivity and specificity data since the databases of chemicals used vary. However these data do show that mammalian cell genotoxicity tests can have low specificity and that combinations of in vitro genotoxicity tests result in high sensitivity for rodent carcinogens and in vivo genotoxicants. High sensitivity has always been a priority of genotoxicity testing strategies recommended by the COM (DOH, 2000). An evaluation of the use of in vitro genotoxicity tests to predict rodent carcinogens and in vivo genotoxicants prepared for the COM meeting in June 2010 (http://www.iacom.org.uk/papers/index.htm MUT/2010/08) concluded that there is no convincing evidence that any rodent carcinogen or in vivo
genotoxicant would fail to be detected by using an *in vitro* genotoxicity test battery consisting of Ames test and MNvit.

36. It is most likely that the few occasions where *in vitro* test strategies fail to detect mutagenic activity (i.e. misleading negative results) will be due to the absence of appropriate metabolic activity *in vitro* (Brambilla and Martelli, 2004). Approaches to resolving potential inadequacies in metabolic activation include structure based metabolism predictions, use of genetically modified target organisms (e.g. CYP2E1 in *Salmonella* YG7108pin3ERb) (Emmert et al., 2006), the use of exogenous metabolic activation systems derived from human sources, or recombinant human cytochrome P450 systems as an external activation system (Ku et al., 2007b).

37. There are a number of MoGAs by which a chemical may demonstrate an *in vitro* genotoxic effect that is either not relevant for humans or has a threshold. The COM has reviewed the evidence for a number of threshold MoGAs and a general guidance statement is available. ([http://www.iacom.org.uk/guidstate/index.htm](http://www.iacom.org.uk/guidstate/index.htm) statement G05). Threshold MoGAs can generally be attributable to non-DNA interactions or an overload of normal cellular physiology. In such cases a **No Observed Effect Concentration** (NOEC) can be determined and may be useful in evaluating risk. Investigations of a threshold-based MoGA need to be designed on a case-by-case basis and can be complex to interpret (Kirkland et al., 2007c).

38. There has been considerable debate regarding the highest concentration that should be used routinely in mammalian cell assays. The International Conference on Harmonisation of the Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is considering whether the maximum concentration tested for pharmaceuticals should be 1mM in mammalian cell genotoxicity assays which would have the effect of reducing the number of misleading positive results due to excessive concentrations where the cellular defence mechanisms might be overwhelmed. However, a reduction to 1mM would not be consistent with the OECD recommendation for a top concentration of 10mM in mammalian cell genotoxicity assays (OECD, 1997). A recent analysis of published data for the top concentration in mammalian cell genotoxicity tests identified a small number of carcinogens that (according to the publications) would not be detected in any part of a three test *in vitro* genotoxicity test battery (consisting of the Ames, mouse
lymphoma and in vitro chromosomal aberration tests) if the testing concentration limit for mammalian cell assays were reduced from 10mM to 1mM (Parry et al., 2010). A further investigation of these carcinogens found that some positive results at concentrations above 1mM were not reproducible (i.e. they were not genotoxic in mammalian cells under current OECD guideline protocols) and others were positive at concentrations below 1mM, particularly when continuous treatments in the absence of S-9 (not included in the original publications) were conducted. A new upper limit for mammalian cells tests of 1mM or 500 µg/ml (whichever is higher) has been proposed as sufficient to detect all genotoxic carcinogens that are negative in the Ames test (Kirkland and Fowler, 2010). Several international organisations are examining the principles underpinning this upper limit selection (e.g ICH, OECD, IGWT) although currently no international consensus has been reached. Precipitation can also be used to define a maximal concentration or upper limit for testing.

39. There has also been considerable investigation of the role of excessive cytotoxicity in mammalian cells and choice of cell type as possible causes of misleading positive results (Blakey et al., 2008; Fellows et al, 2008; Pfuhler, 2009; Pfuhler et al., 2011). The method used to assess cytotoxicity may affect the selection of highest concentration tested and potentially the results obtained using mammalian cell genotoxicity assays (Kirkland et al., 2007b) and recommendations have been made to use cytotoxicity measures based on cell proliferation (Galloway et al., 2011). However, it is important to note that although excessive cytotoxicity may lead to misleading positive results, it may also result in misleading negative results when pronounced cell cycle delay occurs. A similar conclusion was reached at an international symposium on regulatory aspects of genotoxicity testing (Blakey et al., 2008).

40. Most cell lines used for genotoxicity testing lack appropriate metabolism leading to reliance on exogenous metabolic activation systems. These cell lines may often have impaired p53 function and altered DNA repair capacity (Kirkland et al., 2007b). There is some evidence that human lymphocytes are less susceptible to misleading positives than the rodent cell lines currently used (e.g. CHO, V79, CHL). Other cell systems such as the human cell lines HepG2, TK6 and MCL5 cells and the reconstructed human skin models and
HepaRG show promise for future use (Kirkland et al., 2007b; Fowler et al., 2009a; Le Hegarat et al., 2010).

41. The COM agrees that it is not necessary to undertake independent confirmatory *in vitro* tests when clear negative or positive results have been obtained provided the following criteria are satisfied:
   - there is no doubt as to the quality of the study design and the conduct of the test,
   - the spacing and range of test substance concentrations rule out missing a positive response,
   - sufficient treatment conditions and sampling times have been used.

42. It is recognised that it can be difficult to provide convincing evidence for absence of genotoxic effects. The investigator should consider the power of the study design and the past performance of the test system when formulating a protocol in order to optimise the chances of obtaining an unequivocal result from a single experiment and to ensure that any potential genotoxic effect is not missed.

43. There is a need to undertake further *in vitro* genotoxicity testing when an equivocal result is obtained (i.e. neither clearly negative nor clearly positive by appropriate biological or statistical criteria). Such additional genotoxicity tests need to be planned on a case-by-case basis and need not necessarily be undertaken in an identical fashion to the initial experiment(s). Indeed it may be preferable to alter certain aspects of the study (e.g. concentration levels investigated, treatment and sampling times, concentration of metabolic activation mix) so as to obtain supplementary data. It may also be appropriate to use a different genotoxicity test system, e.g. a chromosomal aberration test, if there is equivocal evidence of clastogenicity from an *in vitro* micronucleus test, or an *in vitro* cell mutation assay (e.g. TK or HPRT mutation assays) if there is equivocal evidence of gene mutations from an Ames test.

44. The use of historical negative control data to aid in the interpretation of genotoxicity test results has been considered particularly in relation to equivocal and small magnitude genotoxic effects (Kirkland et al., 2007d). Advice has been recently published on approaches to collecting historical control data. Ideally data should be reported in terms of means and
confidence intervals for the distribution of baseline genotoxic effects rather than observed ranges where outliers can have a disproportionate effect. The dataset should be updated regularly and should be as large as possible. Negative historical control data should have been generated using a fixed testing protocol unless it can be demonstrated that changes in protocol do not impact on the range of values reported in studies (Hayashi et al., 2011).

45. If a chemical is considered on the basis of Stage 1 genotoxicity test results to have *in vitro* mutagenic potential but has not been tested *in vivo*, the COM considers it prudent to assume that the substance may have *in vivo* mutagenic potential.

**Discussion of Stage 1 Strategy: Specific Core Tests**

**In Vitro Bacterial Tests for Gene Mutations**

46. The most widely used *in vitro* mutagenicity test is the bacterial reverse mutation assay for gene mutations developed by Ames and his colleagues using *Salmonella typhimurium* (Gatehouse et al., 1994). The very extensive database available for this assay justifies its inclusion in any initial genotoxicity testing for mutagenic hazard. Several strains of bacteria capable of detecting both base-pair and frame-shift mutations must be included, the validated strains being TA1535, TA1537 (or TA97 or TA97a), TA98 and TA100. In addition, in order to detect oxidising and cross-linking agents, TA102 or a repair proficient *Escherichia coli* strain (WP2 or WP2 (pKM101)) should be included. Testing should be carried out both in the presence and absence of an appropriate exogenous metabolic activation system such as S-9. Both plate-incorporation and pre-incubation methods are widely used and should be considered.

47. There have been developments to automate and minimise the amount of test substance required for the Ames test (e.g. Spiral *Salmonella* mutagenicity assay (Claxton et al., 2001) and Ames II™ test (Fluckiger-Isler et al., 2004)). The Committee considers that these methods have not currently been developed to a point where they can be routinely used for regulatory submissions.
In Vitro Mammalian Cell Micronucleus Assay (MNvit) for Clastogenicity and Aneuploidy

48. The COM recommended in 2000 that equivalent information on clastogenicity could be obtained from the MNvit compared with chromosomal aberration testing in mammalian cells (metaphase analysis) but that aneuploidy could be more easily detected by MNvit. This has since been confirmed in a collaborative trial (Lorge et al., 2006). The COM was aware in 2000 of the ongoing protocol developments and validation of this assay but noted that development of an OECD guideline would take some time. Since 2000 there have been extensive and authoritative investigations of the utility of the in vitro micronucleus assay, and an ECVAM (European Centre for the Validation of Alternative Methods) retrospective validation study concluded that the MNvit is reliable and can be used as an alternative to the in vitro chromosomal aberration for the assessment of clastogenicity and has the benefit of more easily detecting aneuploidy (Corvi et al., 2008). OECD guideline 487 has now been adopted. Many current published in vitro genotoxicity testing strategies recommend that the micronucleus assay and metaphase analysis can be considered as equivalent in the detection of clastogens (Cimino, 2006; Eastmond et al., 2009). However the detection of aneugens in the metaphase test requires non-standard approaches and the COM recommends the MNvit assay as the first choice test for clastogenicity and aneuploidy detection.

49. The MNvit can be carried out in the absence or presence of cytochalasin B, which is used to block cell division and generate binucleate cells (CBMN method). The advantage of using cytochalasin B is that it allows clear identification that treated and control cells have divided in vitro and provides a simple assessment of cell proliferation. The use of cytochalasin B has no impact on the sensitivity of the test results (Garriott et al., 2002, Lorge et al., 2006, Oliver et al., 2006, Wakata et al., 2006). The target population in the presence of cytochalasin B are the binucleate cells (because it is clear they have divided); however scoring of both mononucleated and binucleated cells can be useful for the detection of aneugens (Lorge et al., 2006; Wakata et al., 2006). In the absence of cytochalasin B, it is essential to have evidence that cells have divided.
50. There have been major international collaborative investigations to develop the protocol (Aardema et al., 2006; Clare et al., 2006; Garriott et al., 2002; Kirsch-Volders et al., 2003a; Lorge et al., 2006; Phelps et al., 2002), provide information on the performance of this assay using different cell lines (Oliver et al., 2006; Pfuhler et al., 2011; Wakata et al., 2006) to investigate the most appropriate methods for measuring cytotoxicity (Fellows et al., 2008a; Kirkland, 2010; Lorge et al., 2008). There have also been initial studies to evaluate a flow cytometric approach to the micronucleus assay (Bryce et al., 2008b; Bryce et al., 2007; Laingam et al., 2008). The MNvit can be performed using most mammalian cell lines used in genotoxicity testing (Lorge et al., 2006). However there is emerging evidence that rodent cell lines with compromised p53 activity such as V79, CHO and CHL cells can give more misleading positive results than cell lines proficient for p53 activity such as TK6 and human lymphocytes (Fowler, 2009; Fowler et al., 2009a). Overall the COM’s preference is for human lymphocytes which have a number of advantages over cell lines (e.g. normal diploid primary human cells with some protection against oxidative damage when whole blood cultures are used). If cell lines are used, it is important that the impact of potential genetic drift of the cells cultured is understood (Tweats et al, 2007a).

51. One particular area of protocol development which has been subject to considerable investigation is the most appropriate method(s) for estimating cytotoxicity in MNvit tests (Lorge et al., 2008; Fellows et al., 2008; Kirkland, 2010). It has been suggested that using relative cell counts (RCC) may underestimate cytotoxicity and lead to potentially misleading positive results (Fowler et al., 2009b). In the absence of cytokinesis block, the relative increase in cell count (RICC) or relative population doubling (RPD) are comparable with replication index (RI) used with the cytokinesis block assay and are the most appropriate methods of cytotoxicity estimation. Consensus recommendations embedded in the OECD guideline 487 indicate that the target range for cytotoxicity in the MNvit is 55±5%. Careful selection of toxicity measurements has been shown to reduce the potential for misleading positive results (Fowler et al., 2009b).

52. The in vitro micronucleus assay can be combined with centromere or kinetochore stains, with pancentromeric or chromosome specific centromeric probes using fluorescence in situ hybridisation (FISH) as a sensitive way to discriminate between chromosome breaks, chromosome loss and
chromosome non-disjunction and polyplody (Kirsch-Volders et al., 2002) and therefore is useful in assessing mode of action (Parry, 2006). Binucleate cells obtained with the cytokinesis block methodology (CBMN) will usually be needed for determination of non-disjunction of chromosomes between daughter nuclei. Fenech has proposed that the CBMN assay can be further modified to provide comprehensive information on nucleoplasmic bridges (NPBs) which may provide information on chromosome rearrangements or telomere end fusions, and nuclear buds (NBUDs) which may provide information on gene amplification (Fenech, 2006, 2007). Fenech proposed that the comprehensive CBMN assay should be considered as a ‘cytome’ method for measuring chromosomal instability and altered cellular viability (Fenech, 2006). The ‘cytome’ method is complex and requires considerable technical skill and is currently not suitable for routine testing of chemicals for genotoxicity but may provide useful information on MoGA.

53. The flow-cytometry-based micronucleus assay (FCMMN) has the potential for increased reproducibility and decreased turnaround time for the micronucleus test (Laingam et al., 2008). However the potential still exists for misleading positive results from cell processing or from chemical induced apoptosis and necrosis (Laingam et al., 2008). Approaches to overcoming potential misleading positive results have included: the use of differential staining of micronuclei (MN) and necrotic and apoptotic cells, (Bryce et al., 2008b; Bryce et al., 2007), the use of electronic gating procedures and the use of concurrent assessment of cytotoxicity (Laingam et al., 2008). The FCMMN assay has also been adapted to cell lines which attach to solid surfaces (Bryce et al., 2010). The COM recognises the ongoing validation of the in vitro FCMMN assay which is important before it can be used for regulatory submissions. A separate approach to automation of the CBMN assay involves automated image analysis using Giemsa stained slides (Decordier et al., 2009) which may be useful with appropriate validation.

Discussion Stage 1: Non-Core Tests

In Vitro Chromosomal Aberration Assay in Mammalian Cells (Metaphase Analysis) for Clastogenicity and Aneuploidy

54. The in vitro chromosome aberration assay in mammalian cells has been widely used in genotoxicity testing for many decades and provides
information on genetic damage that may be associated with adverse health outcomes. Only limited information can be obtained on potential aneugenicity by recording the incidence of polyploidy and/or modification of mitotic index (Aardema et al., 1998). The COM notes that polyploidy may not be a reliable indicator for aneugenicity and may result from a number of different genetic changes (Galloway, 2000; Mitchell et al., 1995). It is possible to adapt the chromosome aberration assay to include the use of chromosome specific centromeric probes with FISH to assess the potential for aneuploidy (Maierhofer et al., 2002). An IWGT working group (Galloway et al., 2011) has agreed that the preferred measure of cytotoxicity in the chromosomal aberration test should be one based on cell proliferation (e.g. relative population doubling or relative increase in cell counts) compared to negative control cultures rather than simple cell counts. The available data indicate that the in vitro metaphase analysis and the in vitro micronucleus assay have similar overall performance for determination of clastogenicity. On balance it is considered preferable to use the in vitro micronucleus test for the initial assessment of clastogenic and aneugenic potential.

In Vitro Mouse Lymphoma Assay for Gene Mutation and Clastogenicity

55. The COM reaffirms the view stated in the 1989 and 2000 guidance, that the most appropriate in vitro mammalian cell gene mutation test is the mouse lymphoma assay.

56. Since 2000, there has been considerable development of suitable protocols, negative solvent control data, criteria to define an acceptable positive control response and the use of the Global Evaluation Factor (GEF) and statistical analysis of test results (Clements, 2000; Kirkland et al., 2007a; Moore et al., 2007; Moore et al., 2003; Moore et al., 2006). Many of the published studies were undertaken by the US National Toxicology Program (NTP) and a recent re-evaluation of these results shows many of the studies to be uninterpretable or the outcomes to be equivocal (Schisler et al., 2010). Some authors have reported that the mouse lymphoma assay can detect, in addition to gene mutations and clastogenicity, information on recombination, deletion and aneuploidy (Ogawa et al., 2009; Sofuni et al., 1996; Wang et al., 2009). It is possible that aneuploidy in these cells could be a secondary effect of chromosomal rearrangement. However, the COM considers that this assay is not appropriate for the routine assessment of aneuploidy.
**In Vitro HPRT assays for Gene Mutation**

57. An *in vitro* cell mutation assay which uses forward mutation in the hypoxanthine guanine phosphoribosyl transferase (HPRT) gene to assess mutations has been developed in several cell lines, principally Chinese hamster ovary cells (CHO) cells (Li et al., 1988). It is described in the OECD 476 guideline. The Committee have previously considered the sensitivity of this assay and it was concluded that $10^7$ surviving cells are required for a valid test [http://www.iacom.org.uk/meetings/02.10.2003.htm](http://www.iacom.org.uk/meetings/02.10.2003.htm). Thus, certain mammalian cell gene mutation protocols that have been widely used, particularly some involving CHO cells, are considered to be insufficiently sensitive for the identification of mutagens, predominantly on statistical grounds (UKEMS., 1989).

**In Vitro Assays using Human Reconstructed Skin**

58. A number of research groups have developed genotoxicity assays based on micronuclei measurement using commercial sources of human reconstructed skin (such as Episkin® and EpiDerm™) (Curren et al., 2006; Flamand et al., 2006; Hu et al., 2009; Mun et al., 2009) or a co-culture technique involving reconstructed skin and mouse lymphoma L5178Y cells (Flamand et al., 2006). Proposals for the measurement of DNA damage using the Comet assay in reconstructed skin have also been made (Pfuhler et al., 2011). The primary purpose in developing genotoxicity tests using reconstructed skin has been to supplement genotoxicity data-packages for cosmetic chemicals where no *in vivo* genotoxicity tests are permitted. A tiered approach to testing cosmetic ingredients for genotoxicity has recently been published (Pfuhler et al., 2010).

**In Vitro Alkaline Comet Assay for DNA Damage**

59. The *in vitro* alkaline Comet assay for DNA damage has been proposed as an alternative to clastogenicity assessment in mammalian cells since cell proliferation is not needed, therefore any cell type can be used, and the assay is reported to result in fewer misleading positive results due to cytotoxicity or precipitation than chromosomal aberration tests (Hartmann et al., 2001; Witt et al., 2007). The alkaline Comet assay detects a wide range of genetic damage including single and double strand breaks, repair induced breaks, alkali labile lesions and abasic sites. There is evidence that the *in vitro* Comet assay can be used to detect DNA cross-linking agents (Spanswick et
al., 2010). The Comet-FISH assay has been developed to provide information on site specific DNA strand breaks (Glei et al., 2009; Rapp et al., 2000; Santos et al., 1997). There is evidence that the in vivo Comet assay can detect substances that induce gene mutations in vitro (Kawaguchi et al., 2010; Kirkland and Speit, 2008). Extrapolation from this suggests that the in vitro Comet assay can also detect substances that induce gene mutations and this capability has been demonstrated (Kawaguchi et al., 2010). However, it is not recommended as a routine replacement for gene mutation tests in vitro. Thus, the Comet assay measures DNA damage irrespective of genotoxic end-point, with the exception of aneuploidy. A positive Comet assay result may be due to repairable DNA damage or lesions which lead to cell death and not necessarily mutations or micronuclei. Negative results from an Ames test and MNvit would reduce the level of concern associated with positive results from an in vitro Comet assay. Thus, the in vitro Comet assay can serve as a very useful adjunct to the recommended core-tests, especially in instances where in vivo testing is not permitted such as in cosmetic testing. However, since the Comet assay does not detect aneuploidy, and may report repairable DNA damage, it is not recommended as a core in vitro test.

Summary Stage 1 (In Vitro Genotoxicity Testing)

60. The COM recommendations for Stage 1 testing incorporate a number of changes to the 2000 guidelines, the main changes being the replacement of the in vitro metaphase analysis in mammalian cells with the in vitro micronucleus assay and a reduction from three tests to two in vitro tests for Stage 1. Tests should be undertaken according to the best international guidance available to avoid misleading positive or negative results. Data should be interpreted using appropriate statistical analysis and use of historical negative control data. The COM confirms the need to provide information on gene mutation, clastogenicity and aneugenicity and to understand genotoxic mode(s) of action (MoGA) in order to derive conclusions regarding the biological importance of results. Data on MoGA are important in elucidating whether genotoxicity tests give misleading negative or positive results, and also to aid decisions with regard to devising a strategy for Stage 2 in vivo genotoxicity testing. There is a particular need to understand MoGA for chemicals which cannot be subjected to in vivo
Stage 1: In Vitro Genotoxicity Tests (Figure 3)

Overview of Strategy

Stage 2 of the testing strategy involves an assessment of genotoxic activity in vivo in somatic tissues and in germ cells (when there is a need for the assessment of heritable effects and/or information on hazard classification of mutagens) (see Figure 3). The in vivo genotoxicity testing strategy has to be designed on a case-by-case basis and can be used to address aspects of in vivo mutagenicity, for example;

1) Investigation of mutagenic end point(s) identified in Stage 1,
2) Investigation of genotoxicity in tumour target tissue(s),
3) Investigation of potential for germ cell genotoxicity,
4) Investigation of \textit{in vivo} mutagenicity for chemicals which were negative in Stage 1 but where there is high or moderate and prolonged exposure.

5) Investigation of genotoxicity in site of contact tissues.

It is thus possible for there to be one or more separate Stage 2 strategies designed to assess points 1)-5) for a particular test substance. This rationale leads to different approaches from those advocated by the COM in 2000 where the weight of available evidence suggested that the \textit{in vivo} bone marrow (or peripheral blood) micronucleus assay or bone marrow clastogenicity assay in rodents was the preferred first test in almost all cases. The exception was for direct acting DNA reactive mutagens where a site of contact test was the preferred first test. There was a preference in the 2000 COM guidance for the rat liver UDS assay as a second tissue \textit{in vivo} test, which was selected primarily to provide reassurance of absence of \textit{in vivo} genotoxicity when positive results had been obtained \textit{in vitro} but negative results were obtained in an \textit{in vivo} bone marrow micronucleus or chromosomal aberration assay. The selection of rat liver UDS was based largely on experience in use and the availability of an OECD guideline (DOH, 2000). The revised \textit{in vivo} Stage 2 strategy based on the selection of tests to provide information on one or more specific aspects such as species and/or tissue genotoxicity combined with investigation of particular genotoxic end points and modes of genotoxic action does not necessarily lead to the selection of the rodent bone marrow micronucleus test as the first assay or the rat liver UDS assay as a second tissue assay. A table of \textit{in vivo} genotoxicity tests and end-points is provided in Annex 2.

Other factors that should be considered when determining an \textit{in vivo} genotoxicity testing strategy include whether the testing strategy can be integrated into other regulatory toxicity tests (such as subacute or subchronic toxicity studies). Consideration needs to be given to the nature of the chemical (including physico-chemical properties), the results obtained from \textit{in vitro} genotoxicity tests and the available information on the toxicokinetic and metabolic profile of the chemical (for example when selecting most appropriate species, tissue and end point). The routes of exposure in animal studies should be appropriate to ensure that the substance reaches the target tissue. Routes unlikely to give rise to significant absorption in the test animal should therefore be avoided. Unless systemic exposure can be confirmed from other toxicological studies, or evident toxicity in the target organ is seen,
confirmatory toxicokinetic studies to measure blood or tissue exposure as appropriate should be undertaken to accompany all *in vivo* genotoxicity studies to assess the adequacy of any negative results obtained.

63. The design of *in vivo* genotoxicity tests should incorporate appropriate approaches to reduce the number of animals used in tests, such as the integration of genotoxicity endpoints into repeat-dose studies. Options for reduction in animal usage include:

- use of one sex only (if supported by metabolism data or other data indicating equivalence),
- reduced numbers of sampling times for micronucleus and chromosomal aberration assays when repeat dosing is performed,
- integration of micronucleus and comet end points into repeat-dose toxicity (including *transgenic* mutation) studies, combining micronucleus and Comet assays into a single acute test employing a few administrations of test chemical (Bowen et al., 2011; Pfuhler et al., 2009; Vasquez, 2010),

64. It should also be possible to omit the concurrent positive control administrations in micronucleus, chromosomal aberration and transgenic rodent mutation assays (but not for the Comet assay) where the test facility has appropriate historical positive control data (Pfuhler et al., 2009) as long as positive control slides “banked” from previous treatments and coded in with the experimental slides, are included to demonstrate scoring proficiency.

65. The toxic properties of test substances (such as acute toxicity, subchronic toxicity (including target organ effects), irritancy/corrosivity in contact with skin or mucous membranes), toxicokinetic and metabolism data will influence the choice of route of administration and the highest dose level achievable in *in vivo* mutagenicity tests. Dose selection for *in vivo* genotoxicity testing requires estimation of the maximum tolerated dose, consideration of tissue-specific effects and in some instances (as discussed in paragraph 62), appropriate toxicokinetic data to support tissue exposure to the substances and/or metabolites.

66. The approach outlined to Stage 2 in figure 3 takes account of evidence to suggest that *in vivo* Comet and rodent transgenic mutation assays have better sensitivity and specificity for the identification of rodent carcinogens.
compared with the rat liver UDS test, particularly for carcinogens that are negative in the in vivo micronucleus test (Kirkland and Speit, 2008). The initial in vivo genotoxicity testing strategy should therefore involve selection of one or more of the core Stage 2 tests in rodents; namely, micronucleus tests (accompanied by specific assays for aneuploidy if necessary), the transgenic gene mutation tests, or comet DNA damage assays in rodents. It is acceptable to undertake one in vivo genotoxicity test to investigate a specific mutagenic end point identified from Stage 1 in vitro genotoxicity tests. In some instances there may be a need to investigate more than one end point before reaching a full conclusion on in vivo mutagenic potential.

67. Stage 2 in vivo genotoxicity tests should be undertaken for test substances that are positive in any of the in vitro Stage 1 genotoxicity tests where there is a need to ascertain whether genotoxic activity can be expressed in vivo. There are many reasons why activity shown in vitro may not be observed in vivo (for example, lack of absorption, inability of the active metabolite to reach DNA, rapid detoxication and elimination). Data from in vivo genotoxicity tests are, therefore, essential before any definite conclusions can be drawn regarding the potential mutagenic hazard to humans from test substances which have given positive results in one or more in vitro genotoxicity tests. However, conclusions on mutagenic hazard and MoGA may have to be derived from in vitro genotoxicity data for test substances when no in vivo genotoxicity testing is permitted.

68. In addition, an in vivo genotoxicity test may give positive results for chemical substances which only act in vivo; experience though, has shown that such chemicals are rare (Tweats et al., 2007b). In some instances positive results might be obtained from in vitro genotoxicity tests that are adapted to evaluate specific characteristics of the test substance; for example, by the use of modified or non-standard exogenous metabolising fractions (Muller et al., 2003).

69. Positive results in any Stage 2 genotoxicity test should be assessed for an indication of a MoGA and for evidence which may suggest a threshold of effect or irrelevant positive responses. The COM has previously discussed the relevance of high-dose only positives and recognises that these results may be secondary to non-genotoxic effects rather than being a genotoxic effect of the compound. http://www.iacom.org.uk/statements/COM03S5.htm
Examples of such modes of action in micronucleus tests, include hypothermia or hyperthermia in rodents and compound induced increases in cell division of bone marrow erythroblasts (Blakey et al., 2008; Tweats et al., 2007a; Shuey et al., 2007). If the conclusion is reached that a genotoxic mode(s) of action occurs then the chemical should be considered as an \textit{in vivo} mutagen. MoGA data will be important in considering whether a threshold or non-threshold approach to risk assessment can be used. The COM has published guidance on possible threshold modes of genotoxicity which can include; i) involvement of non-DNA targets, (e.g. aneugen inhibition of microtubules), ii) the contribution of protective mechanisms (e.g. repair of DNA adducts formed from many low molecular weight alkylating agents) and, iii) overload of detoxication pathways (e.g. paracetamol).


70. Supplementary \textit{in vivo} tests should be undertaken if the results of the core \textit{in vivo} genotoxicity test(s) (para 66 and Figure 3) give equivocal results or if there is a need to investigate specific mutagenic endpoints, tumour target organs, or the potential for heritable effects. This may involve repeating all or aspects of the initial Stage 2 testing strategy, or performing supplementary investigations (e.g. mode of action investigations, such as DNA adducts or more specific germ cell testing) to investigate aspects of the genotoxicity of the test substance which have not been resolved. There is a need to select the most appropriate test(s) on a case-by-case basis. All relevant factors, such as results from previous tests, and available information on toxicokinetics, toxicological effects and metabolism of the chemical, should be considered.

71. One aspect of the approach to testing outlined in Figure 3 is that hazard characterisation of germ cell genotoxicity can be included in the initial \textit{in vivo} genotoxicity testing strategy if considered necessary. This is because there are multi tissue \textit{in vivo} genotoxicity assays (e.g. transgenic rodent mutation assays and Comet assay) which can also be used if a need to evaluate germ cell genotoxicity has been established, although further evaluation of these assays for this purpose is recommended. Additionally, germ cell mutation assays might be valuable on a case-by-case basis to provide information on heritable mutagenic effects, but these would form part of a supplementary \textit{in vivo} genotoxicity testing strategy, if considered appropriate.
The COM reaffirms that a chemical considered a positive in vivo somatic cell mutagen should also be considered as a possible germ cell mutagen unless data can be provided to the contrary. The position held previously, that most if not all germ cell mutagens are also genotoxic in somatic cells still holds true. It has been noted that there are some rare examples (e.g. sodium orthovanadate, Attia et al., 2005) where the mouse bone marrow micronucleus assay does not predict germ cell genotoxicity. However, the data on such compounds are conflicting and it is not known, for example, whether somatic mutations would have been identified if other test systems (e.g. transgenic assays) had been used (Attia et al., 2005; Ciranni et al., 1995; Witt et al., 2003). It is possible these examples may relate to cellular targets in germ cells that are not present in the bone marrow (e.g. different proteins in chromatin structure and processes involved in meiosis). However, induction of other genotoxic effects and in other tissues cannot be excluded. There are also examples of germ cell mutagens which affect specific stages of gametogenesis in males (Adler, 2008) and where there are differences between male and female germ cell genotoxicity (Bishop, 2003).

It is plausible that other targets during the process of meiotic cell division may be unique to germ cells but not necessarily identical in both sexes (Pacchierotti et al., 2007). The COM considers that further research to understand better the effects of genotoxic substances on mammalian germinal cells may be informative with regard to genotoxicity testing strategies in the future. It is noted that some initial results with oocyte in vitro and in vivo systems have provided information on germ-cell specific modes of action (Ranaldi et al., 2008; Vogt et al., 2008; Yin et al., 1998).

Discussion of Stage 2 Initial Testing Strategy - General Aspects

There are many recent publications debating in vivo genotoxicity testing strategies. For example, the GUM (German speaking section of the European Environmental Mutagen Society) recommended a single study using a combined analysis for micronuclei and comet induction in selected tissues (Pfuhler et al., 2007), while the WHO/IPCS recommended cytogenetics (bone marrow) or gene mutation or alternative tests as defined by genotoxic end-point, chemical class and reactivity (with consideration of factors such as bioavailability and metabolism) (Eastmond et al., 2009). The in vivo genotoxicity testing strategy recommended by the COM acknowledges there can be a variety of reasons for undertaking in vivo genotoxicity tests.
and it is important to identify clearly the critical aspects of \textit{in vivo} genotoxicity to be addressed (as set out in the Overview of Stage 2 strategy; paras 61-73) in order to develop a strategy accordingly, rather than simply specify preferred first and second tests. There are less data on the performance of \textit{in vivo} genotoxicity assays for prediction of rodent carcinogenicity compared to data on the performance of \textit{in vitro} genotoxicity tests. Transgenic rodent mutation assays and the \textit{in vivo} micronucleus assay have been shown to exhibit complementarity regarding prediction of rodent carcinogenicity, consistent with the assessment of different mutagenic end-points by these two assays. Transgenic rodent mutation assays were usually positive for those carcinogens which were positive in \textit{in vitro} gene mutation tests in bacteria whilst the \textit{in vivo} MN assay had greater predictivity for carcinogens positive in the \textit{in vitro} metaphase analysis in mammalian cells (Lambert et al., 2005). Thus genotoxic end-point and MoGA analysis of \textit{in vitro} mutagenic activity is of considerable importance in helping to develop an initial \textit{in vivo} genotoxicity testing strategy. The COM recommends that the initial \textit{in vivo} genotoxicity testing strategy should be based on one or more tests selected from a relatively limited number of \textit{in vivo} genotoxicity tests that have been specifically designed to provide the optimum amount of information on \textit{in vivo} mutagenic potential of the test substance.

\section*{Discussion of Stage 2 - Recommended \textit{In Vivo} Genotoxicity Tests}

\textit{In Vivo} Bone Marrow and Peripheral Blood MN Assay for Clastogenicity and Aneuploidy

\textit{In Vivo} Bone Marrow CA Assay for Clastogenicity

76. The \textit{in vivo} bone marrow micronucleus assay is still the most widely used \textit{in vivo} genotoxicity test. Most of the available \textit{in vivo} data on the mutagenicity of chemicals have been obtained from studies using the bone marrow micronucleus assay (BMMN) in mice. The bone marrow is readily accessible to chemicals that are present in the blood and a wide range of structurally diverse clastogens and aneugens has been detected using these methods. The BMMN assay detects clastogenicity by measuring micronuclei (MN)
formed from acentric chromosome fragments in young (polychromatic) erythrocytes in the bone marrow (or reticulocytes of peripheral blood). It may also be used to identify the induction of numerical aberrations. Micronuclei containing whole chromosomes (as opposed to fragments) can be identified with molecular kinetochore or centromeric labelling techniques. It should be noted that only aneuploidy produced by chromosome loss can be measured in the BMMN assay. The use of peripheral blood is an alternative approach for both mice (CSGMT, 1995) and rats (when the youngest fraction of reticulocytes are sampled) which provides equivalent data to the bone marrow assay and is technically less demanding (Rothfuss, 2011; Suzuki et al., 2005a; Torous et al., 2000; Wakata et al., 1998). High throughput approaches to the peripheral blood micronucleus assay have been published (De Boeck et al., 2005; Torous et al., 2000). The rodent micronucleus assay can be used in the initial in vivo genotoxicity strategy for generic testing for in vivo mutagenic potential and for assessment of clastogenicity and aneuploidy. Clastogenicity may be measured by metaphase analysis of chromosomal aberrations (CA) in bone marrow of rodents as an alternative approach to the use of the micronucleus assay.

77. Proposals have been published to incorporate micronucleus assays into routine rodent 28 day subacute toxicity studies which have demonstrated the feasibility of such an approach (Hamada et al., 2001; Krishna et al., 1998; Madrigal-Bujaidar et al., 2008). The development of a simultaneous liver and peripheral blood micronucleus assay in young rats has also been reported (Suzuki et al., 2005). The evidence from one evaluation of micronucleus tests conducted on samples from short-term, subchronic and from a few chronic studies in mice has been published. In mice, MN in polychromatic erythrocytes represent DNA damage occurring in the last 72h, whilst MN in normochromatic erythrocytes represent average damage during the 30 day period prior to sampling (Witt et al., 2000).

Transgenic Rodent Mutation (TGR) Assay for Gene Mutations

78. There has been a significant increase in the number of studies undertaken with transgenic rodent mutation assays published since the COM guidance in 2000. These have been comprehensively reviewed (Lambert et al., 2005). There are sufficient data to assess the performance of the Muta™™ mouse, BigBlue® mouse and rat (including use of λ cII transgene), LacZ plasmid mouse, and the gpt delta mouse models. The transgenic rodent mutation
assays can be used to assess gene mutations in a wide range of rodent tissues (including germ cells) using all routes of administration (Lambert et al., 2005) and is particularly valuable when investigating gene mutation as the genotoxic endpoint. Transgenic rodent mutation assays have been reported to produce data that are generally compatible with the mouse specific locus test for germ line mutagens (Singer et al., 2006). In addition transgenic rodent mutation assays can be particularly useful for in vivo site-of-contact mutagen assessment (Dean et al., 1999). Guidance on appropriate approaches to protocol development have been published by the IWGT (Thybaud et al., 2003). Molecular sequencing of induced mutations in transgenic targets can aid in interpretation of study results (particularly equivocal responses) and also provide mechanistic information. Further information particularly on non-carcinogens is required to assess the overall performance of transgenic rodent mutation assays although the available data suggests the best positive and negative predictivity was obtained using results from in vitro Salmonella mutagenicity tests and in vivo transgenic rodent mutation assays (Lambert et al., 2005). There is a need to consider and validate the optimal protocol when using transgenic mutation tests with tissues with a slow turnover. The OECD published a Detailed Review Paper (DRP) on Transgenic Rodent Gene Mutation Assays in 2009 and recommended the development of an OECD guideline (OECD, 2009). An OECD guideline was adopted in July 2011. http://www.oecd-ilibrary.org/environment/test-no-488-transgenic-rodent-somatic-and-germ-cell-gene-mutation-assays_9789264122819-en

Rodent Comet Assay for DNA Damage

79. The in vivo Comet assay detects a wide spectrum of DNA damage including repairable DNA damage. An overview of the types of genetic lesions detected is given above in paragraph 59. The in vivo Comet assay can detect substances that induce gene mutations and has produced positive results for nearly 90% of rodent carcinogens not detected by the rodent bone marrow MN assay (Kirkland and Speit, 2008). There have been significant developments with regard to the conduct of the in vivo alkaline Comet assay since 2000 (Burlinson et al., 2007; Brendler-Schwaab et al., 2005; Hartmann et al., 2004). This assay can be used for elucidating positive in vitro genotoxicity findings and to evaluate genotoxicity in target organs of toxicity (Hartmann et al., 2004), however, it would not be an appropriate follow-up for
a substance causing aneuploidy \textit{in vitro}. There is now consensus agreement on a protocol for most tissues which would be consistent with an OECD guideline (Burlinson et al., 2007). The Comet assay can be applied to a wide range of species and in many tissues including site-of-contact tissues. In the absence of data indicating particular tissues of interest (e.g. toxic findings or tissue accumulation seen in other studies), comet analysis of the stomach/duodenum (to detect site of contact effects), and liver (to detect genotoxic metabolites) should be studied. The Committee considers that the \textit{in vivo} Comet assay has appropriate sensitivity to detect chemicals which induce both gene mutations and/or clastogenicity. With regard to the assessment of germ cell genotoxicity, measurement of DNA effects by the Comet assay in sperm requires additional steps for chromatin decondensation. A protocol for standardisation of the germ cell Comet assay has not yet been achieved (Speit et al., 2009). Thus the \textit{in vivo} Comet assay can be used as a core test in the initial \textit{in vivo} genotoxicity testing strategy to assess DNA damage in multiple tissues in a single study and it is possible to include the Comet assay within standard regulatory toxicity tests (Rothfuss et al., 2010) or within other \textit{in vivo} genotoxicity tests (Vasquez, 2010).

\textit{Non-Core In Vivo Test: Rat Liver UDS Assay for DNA Damage}

80. The rodent liver UDS assay is an established approach for investigating genotoxic activity in the liver (Kennelly et al., 1993). The endpoint measured is indicative of DNA damage and subsequent repair in liver cells. The COM consideration of this assay and published evaluations suggest it gives broadly similar results to the \textit{in vivo} Comet assay with regard to identification of genotoxicity in the liver (http://www.iacom.org.uk/statements/UDS.htm). An analysis of the prediction of rodent carcinogens not identified by the micronucleus tests indicated that the Comet assay was considerably better than the rat liver UDS assay at identifying rodent carcinogens (Kirkland and Speit, 2008). The COM’s preference is to use the Comet assay rather than rodent liver UDS in order to assess \textit{in vivo} potential for DNA damage.

\textbf{Discussion of Stage 2-Supplementary Tests.}

81. Supplementary \textit{in vivo} genotoxicity tests need to be considered on a case-by-case basis taking into account all relevant information. It is considered that for most chemicals, supplementary \textit{in vivo} genotoxicity data should be
unnecessary but on a case-by-case basis specific aspects of MoGA (e.g. nature of DNA adducts) and further characterisation of germ cell genotoxicity (e.g. characterisation of male and/or female germ cell clastogenicity including use of FISH, and the evaluation of heritable effects) may be required. DNA adduct studies can provide valuable information on potential genotoxicity as a follow up for *in vitro* mutagens which have yielded negative results in *in vivo* genotoxicity assays (Phillips et al., 2000). DNA adduct data (including type of adduct, frequency, persistence, repair process) can be used to inform on MoGA and its relationship to carcinogenesis, and should be considered in conjunction with other relevant data such as dosimetry, toxicity, genotoxicity and tumour data (Jarabek et al., 2009).

82. A brief outline of these additional Stage 2 methods is given in Table 1 below. Reference is also made in Table 1 to a number of tests for heritable genotoxic effects but it is noted that these tests, which involve the use of many animals and demand a high level of expertise, are comparatively rarely used. The COM is aware that there is the possibility that gender differences in germ cell mutagenesis may exist and this aspect may need to be considered on a case-by-case basis (Eichenlaub-Ritter et al., 2007).
## Table 1. Supplementary *in vivo* genotoxicity tests.

<table>
<thead>
<tr>
<th>Assay</th>
<th>Endpoint</th>
<th>Guidance</th>
<th>Main Attributes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Investigations of DNA Adducts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>³²P</em>-postlabelling</td>
<td>DNA adducts</td>
<td>IWGT</td>
<td>Can be highly sensitive particularly with bulky adducts and if appropriate enrichment technique used.</td>
<td>Interpretation of results can be complex. Involves handling high-activity <em>³²P</em>. (Phillips et al., 2000)</td>
</tr>
<tr>
<td>Covalent binding to DNA</td>
<td>DNA Adducts</td>
<td>IWGT</td>
<td>Some methods (AMS) are potentially very sensitive and can provide data on DNA binding at levels of exposure similar to low level environmental exposures</td>
<td>Uses radiolabelled compound (very small amounts (e.g. nanograms) in the case of AMS). Interpretation of results can be complicated (e.g. by non-specific binding). (Himmelstein et al., 2009)</td>
</tr>
<tr>
<td><strong>Supplementary investigations of germ cell mutagenicity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analysis for clastogenicity/aneuploidy</td>
<td>Structural and numerical changes in spermatogonia, spermatocytes or oocytes</td>
<td>OECD</td>
<td>Can provide information on nature of effects in spermatogonia, spermatocytes and/or oocytes of mice or rats</td>
<td>Can provide useful information on MoGA. (Russo, 2000)</td>
</tr>
<tr>
<td>Spermatid micronucleus assay</td>
<td>Chromosomal aberrations and/or lagging chromosomes</td>
<td>None</td>
<td>Provides information of clastogenic and/or aneugenic effects in spermatocytes.</td>
<td>(Allen et al., 2000)</td>
</tr>
<tr>
<td>Dominant lethal assay</td>
<td>Chromosomal/gene mutations</td>
<td>OECD</td>
<td>Provides information on unstable chromosomal changes in gametes that lead to fetal death after fertilization and can determine stage(s) of gametogenesis affected</td>
<td>Little used. needs relatively large numbers of animals (Adler et al., 1994)</td>
</tr>
<tr>
<td>Mouse specific locus test</td>
<td>Gene mutations</td>
<td>EPA</td>
<td>Provides information on genetic changes transmitted to the first generation progeny as basis for estimation of induced mutation frequency in humans</td>
<td>Very rarely used. Needs large numbers of animals (Adler, 2008)</td>
</tr>
<tr>
<td>Mouse heritable translocation test</td>
<td>Chromosomal changes</td>
<td>EPA</td>
<td>Provides information on chromosomal changes transmitted to the first generation progeny as basis for estimation of induced translocation frequency in humans</td>
<td>Very rarely used. Needs large numbers of animals (Adler, 2008)</td>
</tr>
<tr>
<td>Sperm Comet assay</td>
<td>Double strand breaks and/or apurinic sites in sperm head DNA</td>
<td>None</td>
<td>Provides information on genetic instability in sperm</td>
<td>(Trivedi et al., 2010)</td>
</tr>
<tr>
<td>Spermatid UDS assay</td>
<td>Repair DNA synthesis in spermatocytes</td>
<td>EPA</td>
<td>Provides information on induction of DNA lesions</td>
<td>(Sotomajor and Sega, 2000)</td>
</tr>
</tbody>
</table>
Summary Stage 2 (*In Vivo* Genotoxicity Testing).

83. The *in vivo* genotoxicity testing strategy has to be designed on a case-by-case basis and can be used to address aspects of *in vivo* mutagenicity, for example;

1) Investigation of mutagenic end point(s) identified in Stage 1,

2) Investigation of genotoxicity in tumour target tissue(s),

3) Investigation of potential for germ cell genotoxicity,

4) Investigation of *in vivo* mutagenicity for chemicals which were negative in Stage 1 but where there is high or moderate and prolonged exposure.

5) Investigation of genotoxicity in site of contact tissues.

The recommended *in vivo* genotoxicity test(s) include micronucleus assay, bone marrow cytogenetics, Comet assay in rodents and transgenic rodent mutation assay. In some instances there may be a need to undertake more than one *in vivo* test to perform an initial assessment of *in vivo* mutagenic potential (e.g. where endpoints cannot be assessed in one study and there is a need to investigate multiple end points before reaching conclusions on *in vivo* mutagenic potential). Multiple endpoints may be combined in a single study. If positive results are obtained it is important to consider the evidence for genotoxic mode of action and check the data for evidence of irrelevant positive results. Usually negative results obtained in a carefully selected *in vivo* test (possibly studying more than one endpoint and tissue) will be sufficient to address positive results found *in vitro*. However, a further test(s) may be needed if some of the genotoxic effects seen in Stage 1 *in vitro* tests had not been adequately studied *in vivo* (e.g. the chemical affects multiple mutagenic end-points), or other aspects of the genotoxic potential of the chemical had not been fully resolved (e.g. in the case where an investigation of heritable effects was required). If equivocal results are obtained, then supplementary testing may be needed. This may involve repeating some aspects of the recommended *in vitro* and/or *in vivo* genotoxicity tests, or performing additional investigations (e.g. MoGA investigations, such as DNA adducts and/or more detailed consideration of heritable effects). The supplementary *in vivo* genotoxicity testing strategy should be devised on a case-by-case basis. There is a need to select the most appropriate assay(s)
on a case-by-case basis. All relevant factors such as results from previous tests, structural alerts and available information on toxicokinetics and metabolism of the substance, should be considered. In the absence of appropriate germ cell genotoxicity data, the COM considers it is reasonable to assume that all somatic cell mutagens have the potential to be germ cell mutagens.

**Possible Future Developments**

84. The COM is aware that new assays and toxicogenomic approaches are under development which might be of value within genotoxicity testing. These include the detection of gene mutations at the endogenous phosphatidylinositol glycan complementation group A gene (Pig-A), a reporter gene in which mutations are currently detected in peripheral red blood cells of mammals (Bryce et al., 2008a; Dertinger et al., 2011; Miura et al., 2009). This assay has potential advantage of integration into regulatory toxicity tests (Dertinger et al., 2010) and it is noted that Pig-A mutations increase with duration of dosing (Miura et al., 2009). Other potential tests include investigation of instability in expanded simple tandem repeats in male gametes and offspring to evaluate heritable mutations (Singer et al., 2006). The development of new high throughput assays for the assessment of germ line mutations and the quantification of risk from such data may provide opportunities to protect future generations from mutated DNA sequences. Developments within the field of toxicogenomics are also likely to provide new methods for investigating genotoxic mechanisms and informing on MoGA. The COM have reviewed data generated in this field several times during 2008 and 2009 up to the drafting of this guidance statement but currently conclude that the evidence does not support the routine use of toxicogenomic approaches as an adjunct to genotoxicity testing (http://www.iacom.org.uk/papers/index.htm). A recent workshop held by the ILSI-HESI (Health Effects Institute) IVGT (In Vitro Genetic Toxicity Testing) Project Committee reviewed 16 assays/technologies which were at various stages of development (defined as emerging to mature). The workshop highlighted emerging approaches to genotoxicity testing such as Enzyme-DNA films and DNA adductome studies (Lynch et al., 2011).
Annex 1: Sensitivity and Specificity Data Considered by the COM

1. Data for sensitivity (correct identification of rodent carcinogens) and specificity (correct prediction of non-carcinogens as assessed in rodent carcinogenicity bioassays) have been obtained from a number of publications. Information is available for (Q)SAR approaches, screening tests and *in vitro* genotoxicity assays.

2. The figures quoted depend on the carcinogenicity data set used (e.g. Gold Carcinogenicity Potency database (http://potency.berkeley.edu/)), the classification of genotoxicity test results (i.e. positive, negative, equivocal based on study authors results or subjected to independent peer review) and whether equivocal and/or technically compromised (inadequate) test results have been included in the analyses. Sensitivity/specificity data for genotoxicity tests using a sub-set of genotoxic carcinogens have not been published, because this would require considerable work to evaluate the mode of action for carcinogenicity for a large number of chemicals. Specificity data for identification of chemicals with no *in vivo* genotoxic activity (non-genotoxins) have not been published, as there are no published databases for such chemicals.

3. The sensitivity and specificity data that have been reviewed by the COM are tabulated in Annex 1, Tables 1-3 (rounded to whole numbers). The list of tests for each stage is not necessarily exhaustive.

<table>
<thead>
<tr>
<th>Table</th>
<th>Data Source</th>
<th>Sensitivity/Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(Q)SAR</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Screening Tests</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td><em>In vitro</em> Genotoxicity Assays</td>
<td></td>
</tr>
<tr>
<td>Method</td>
<td>Sensitivity Identification of mutagens or rodent carcinogens</td>
<td>Specificity Identification of non-mutagens or rodent non-carcinogens</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------------------------------------</td>
<td>-----------------------------------------------------------------</td>
</tr>
<tr>
<td>DEREK</td>
<td>No data reported</td>
<td>No data reported</td>
</tr>
<tr>
<td>TOPKAT</td>
<td>No data reported</td>
<td>No data reported</td>
</tr>
<tr>
<td>MDL QSAR</td>
<td>81%</td>
<td>76%</td>
</tr>
<tr>
<td>MultiCASE (MC4PC)</td>
<td>71% (bacterial) 63% (mouse lymphoma) 44% (clastogenicity in vitro) 53% (clastogenicity)</td>
<td>88% (bacterial) 74% (mouse lymphoma) 92% (clastogenicity in vitro) 75% (clastogenicity)</td>
</tr>
<tr>
<td>Toxtree (version 1.50)</td>
<td>74% (rodent carcinogenicity) 85% (bacterial mutagenicity)</td>
<td>64% (rodent carcinogenicity) 72% (bacterial mutagenicity)</td>
</tr>
</tbody>
</table>
### Annex 1 Table 2 Screening Tests

<table>
<thead>
<tr>
<th>Method</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Comments/references</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepG2 (cystatin, p53, Nrf2) luciferase reporter</td>
<td>85% (17/20 ECVAM list)  74% (bacterial mutagenicity)  45% (clastogenicity)</td>
<td>81% (34/42 ECVAM list)  80% (bacterial mutagenicity)  83% (clastogenicity)</td>
<td>62 ECVAM listed chemicals, 192 additional chemicals (Westerink et al., 2010)</td>
</tr>
<tr>
<td>Vitotox™ (bacterial SOS reporter assay for mutagenicity) RadarScreen (RAD54 reporter assay in yeast for clastogenicity)</td>
<td>70% bacterial mutagenicity (14/20 ECVAM list)  86% (bacterial mutagenicity).  70% clastogenicity (14/20 ECVAM list),  77% (clastogenicity)</td>
<td>93% (39/42 ECVAM list)  94% (bacterial mutagenicity)  83% clastogenicity (35/42 ECVAM list)  74% (clastogenicity)</td>
<td>62 ECVAM listed chemicals, 192 additional chemicals (Westerink et al., 2009)</td>
</tr>
<tr>
<td>GADD45a-GFP</td>
<td>18/20 ECVAM list of mammalian cell mutagens (90%)  95% for genotoxic carcinogens  63% (regulatory battery of Ames, CA/MNVit, or CA/MLA)  94% of genotoxicants  30% (in vitro genotoxicants)  30% (rodent carcinogens)</td>
<td>22/23 ECVAM list of mammalian cell non-mutagens (96%)  100% non-carcinogens  100% (regulatory battery of Ames, CA/MNT or CA/MLA)  83% non-genotoxicants  97% (in vitro genotoxicants)  88% (rodent carcinogens)</td>
<td>(Birrell et al., 2010)  75 compounds studied (Hastwell et al., 2006)  Validation data for 56 compounds requiring metabolic activation (Jagger et al., 2008)  57 in vitro genotoxicants 50 chemicals with rodent carcinogenicity data. (Olaharski et al., 2009)</td>
</tr>
</tbody>
</table>

a: accurate prediction of positive responses compared to comparator dataset, given in parenthesis  
b: accurate prediction of negative responses compared to comparator dataset, given in parenthesis
## Annex 1 Table 3 Genotoxicity Tests (in vitro) in Relation to Rodent Carcinogenicity

<table>
<thead>
<tr>
<th>Method</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Comments/references</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ames</td>
<td>59%</td>
<td>74%</td>
<td>541 chemicals (Kirkland et al., 2005a)</td>
</tr>
<tr>
<td>Ames</td>
<td>52%</td>
<td>72%</td>
<td>3711 chemicals including tests with <em>Salmonella</em> and <em>Escherichia</em> (Matthews et al., 2006a)</td>
</tr>
<tr>
<td>Micronucleus (in vitro)</td>
<td>79%</td>
<td>31%</td>
<td>89 chemicals (Kirkland et al., 2005a)</td>
</tr>
<tr>
<td>Micronucleus (in vitro)</td>
<td>88%</td>
<td>23%</td>
<td>182 chemicals (Matthews et al., 2006a)</td>
</tr>
<tr>
<td>Chromosomal aberrations (in vitro)</td>
<td>66%</td>
<td>45%</td>
<td>352 chemicals (Kirkland et al., 2005a)</td>
</tr>
<tr>
<td>Chromosomal aberrations (in vitro)</td>
<td>55%</td>
<td>63%</td>
<td>1391 chemicals (Matthews et al., 2006a)</td>
</tr>
<tr>
<td>Mouse lymphoma assay</td>
<td>73%</td>
<td>39%</td>
<td>245 chemicals (Kirkland et al., 2005a)</td>
</tr>
<tr>
<td>Mouse lymphoma assay</td>
<td>71%</td>
<td>44%</td>
<td>827 chemicals (Kirkland et al., 2005a; Matthews et al., 2006a)</td>
</tr>
<tr>
<td>Ames + Micronucleus* combined</td>
<td>94%</td>
<td>12%</td>
<td>372 chemicals. Positive results in at least one test (Kirkland et al., 2005a)</td>
</tr>
<tr>
<td>Ames + mouse lymphoma* combined</td>
<td>89%</td>
<td>32%</td>
<td>436 chemicals (Kirkland et al., 2005a)</td>
</tr>
<tr>
<td>Ames + mouse lymphoma + Chromosomal aberrations combined</td>
<td>84%</td>
<td>23%</td>
<td>202 chemicals (Kirkland et al., 2005a)</td>
</tr>
<tr>
<td>Ames + mouse lymphoma + Micronucleus* combined</td>
<td>91%</td>
<td>5%</td>
<td>54 chemicals (Kirkland et al., 2005a)</td>
</tr>
</tbody>
</table>

*Positive results in at least one test
a: accurate prediction of rodent carcinogenicity
b: accurate prediction of rodent non-carcinogenicity
Annex 2. Tabulation of Genotoxicity Tests (in Stages 1 and 2) and Mutagenic/Genotoxicity End Points Detected.

<table>
<thead>
<tr>
<th>Genotoxicity test</th>
<th>Mutagenic/genotoxicity end point detected</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In vitro assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ames</td>
<td>Gene mutation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Responds to wide range of DNA reactive mutagens when full set of <em>S. typhimurium</em> tester strains and <em>E. coli</em> with appropriate exogenous metabolic activation used.</td>
</tr>
<tr>
<td>Micronucleus test</td>
<td>Clastogenicity, aneuploidy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Centromere or kinetochore stains, with pancentromeric or chromosome specific centromeric probes using fluorescence in situ hybridisation (FISH) are required for aneuploidy.</td>
</tr>
<tr>
<td>Chromosomal aberrations</td>
<td>Clastogenicity, aneuploidy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indications of aneuploidy from induction of polyploidy or increased mitotic index, but the use of chromosome specific centromeric probes fluorescence in situ hybridisation (FISH) required to assess the potential for aneuploidy. Very similar assay performance compared with micronucleus test.</td>
</tr>
<tr>
<td>Mouse Lymphoma Assay</td>
<td>Gene mutation, clastogenicity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Distribution of large and small colony mutants can give information on induction of gene mutations versus clastogenicity. No convincing evidence that MLA can detect aneuploidy consistently.</td>
</tr>
<tr>
<td>Comet assay</td>
<td>DNA strand breaks and alkali labile sites</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can respond to a wide range of gene mutagens and clastogens but gives no information about modes of mutagenic action.</td>
</tr>
<tr>
<td><strong>In vivo assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodent Bone Marrow/peripheral blood micronucleus assay</td>
<td>Clastogenicity, aneuploidy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A wide range of structurally diverse clastogens have been detected. Can also be used to investigate aneuploidy by use of centromere or kinetochore probes.</td>
</tr>
<tr>
<td>Rodent transgenic mutation assay</td>
<td>Gene mutations</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Valuable for the investigation of gene mutation in a wide range of tissues including germ cells and particularly to confirm gene mutation as a mode of action.</td>
</tr>
<tr>
<td>Rodent Comet assay</td>
<td>DNA strand breaks, alkali labile sites</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can respond to a wide range of gene mutagens and clastogens but gives no information about modes of mutagenic action. Valuable for detection of DNA damage in a wide range of tissues.</td>
</tr>
<tr>
<td>Rodent Liver UDS</td>
<td>Unscheduled synthesis DNA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Endpoint measured is indicative of DNA damage and subsequent repair in liver cells.</td>
</tr>
</tbody>
</table>
Annex 3:

Rationale for Selection of Ames Test and *In Vitro* Micronucleus Assay as The Two Principal *In Vitro* Assays. (Kirkland et al., 2011)

1. An evaluation of the use of *in vitro* genotoxicity tests to predict rodent carcinogens (557 chemicals evaluated) and *in vivo* genotoxicants (405 chemicals evaluated) was prepared and updated for the COM meeting in June 2010 ([http://www.iacom.org.uk/papers/index.htm MUT/2010/08](http://www.iacom.org.uk/papers/index.htm)). A two-test battery consisting of the Ames test plus *in vitro* micronucleus tests correctly identified 73% of rodent carcinogens. This is lower than in the published sensitivity analysis of Kirkland et al (Kirkland et al., 2005a), because in the current analysis the *in vitro* chromosomal aberration test was accepted as a surrogate for the *in vitro* micronucleus test where no data existed for the latter, as the concordance between the 2 tests for detection of clastogens is so high. Thus, the denominator used in the calculation of sensitivity for the current 2-test battery, by taking either *in vitro* micronucleus or *in vitro* chromosomal aberration results, is correspondingly larger than in the Kirkland et al paper (Kirkland et al., 2005a) and lower sensitivity is reported. By adding the MLA as a third *in vitro* test, the sensitivity increased marginally to 75%, but of the additional 11 carcinogens, 10 had not been tested in the *in vitro* micronucleus test and so it is not known whether they would also have been positive in the *in vitro* micronucleus as well as in the MLA.

2. A two-test battery of an Ames test and the *in vitro* micronucleus tests correctly detected 78% of *in vivo* genotoxicants. By adding the MLA as a third test the sensitivity increased marginally to 80%, but of the additional 6 *in vivo* genotoxicants, 4 had not been tested in the *in vitro* micronucleus test and so it is not known whether they would also have been positive in the *in vitro* micronucleus as well as in the MLA. From both rodent carcinogen and *in vivo* genotoxicants databases there were only four chemicals for which there was some evidence that the MLA may be more sensitive than the *in vitro* micronucleus. However, the data are not convincing for the following reasons:

A. Toluene was reported positive in the NTP MLA study, but has subsequently been re-evaluated as equivocal in the analysis of (Schisler et al., 2010), and was not found positive in a rigorous MLA conducted to higher concentrations and >80% toxicity (Kirkland and Fowler, 2010).
B. Benzyl acetate was reported positive in the NTP MLA study, and subsequently re-evaluated as positive by Schisler et al (2010), but an expert panel review (Mitchell et al, 1997) identified this chemical as "untestable" in the MLA because it reacts with the plastic of the culture vessels and may thus produce artefacts.

C. Morphine was negative in a non-standard in vitro micronucleus test in which mouse splenocytes were treated only for 21 hr in the absence of metabolic activation. It is possible that morphine may induce micronuclei when tested at higher concentrations over shorter periods in the absence and presence of metabolic activation in a standard assay.

D. Thiabendazole is an aneugen which, typically, has a very steep dose response. It has been found positive for induction of micronuclei in vitro in several papers, but is reported equivocal or negative in other papers, possibly because optimum concentration spacing, treatment and sampling times were not used.

3. Whilst re-testing of these four chemicals, and of several others for which neither in vitro micronucleus or chromosomal aberration data exist (Kirkland et al., 2010), could provide additional reassurance, the Committee concluded that, based on the large amount of available data, there is no convincing evidence that any rodent carcinogen or in vivo genotoxicant would fail to be detected by using an in vitro genotoxicity test battery consisting of Ames test and in vitro micronucleus test. Summary analyses of sensitivity for the combination of Ames and micronucleus tests are provided in Annex 1.

4. The revised strategy of two tests (Ames and MNvit) allows for the efficient identification of all mutagenic end-points but, by reducing the number of mammalian cell tests from that recommended by COM in 2000, and following improved methodologies, the risk of misleading positive results is decreased.
Annex 3 Table 1: Further data on combinations of genotoxicity tests

<table>
<thead>
<tr>
<th>Chemicals evaluated</th>
<th>Sensitivitya Ames +MN*</th>
<th>Sensitivitya Ames +MN* +MLA</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>557 rodent carcinogens</td>
<td>73% (409/557). Remainder were negative, negative but technically compromised, weak, equivocal or inconclusive/insufficient detail.</td>
<td>75% (420/557) Of the additional 11 carcinogens identified by MLA, 10 were not tested in MN.</td>
<td>No convincing evidence any rodent carcinogens would fail to be detected by Ames + MN.</td>
</tr>
<tr>
<td>409 in vivo genotoxicant</td>
<td>(78%) 317/409 Remainder were negative, but technically compromised, weak, equivocal or inconclusive/insufficient detail.</td>
<td>(79%) 323/409 4/6 of the additional in vivo genotoxicants detected by MLA had not been tested in either MN or CA.</td>
<td>No convincing evidence that any in vivo genotoxicants would fail to be detected by Ames + MN.</td>
</tr>
</tbody>
</table>

a: accurate prediction of either rodent carcinogenicity or in vivo genotoxicity (see chemicals evaluated column)

* chromosomal aberration data where no micronucleus test was available. Abbreviations MN= micronucleus test, MLA = mouse lymphoma assay, CA= chromosomal aberration assay

Data presented to COM at the 17 June 2010 meeting http://www.iacom.org.uk/papers/documents/MUT2010-08Slides.pdf (Kirkland et al., 2011) and subsequently up-dated in light of re-evaluation of NTP MLA results (Schisler et al., 2010)
References


Attia, S.M., Badary, O.A., Hamada, S., de Angelis, M.H., and Adler, I.D. (2005). Othovanadate increased the frequency of aneuploid mouse sperm without micronucleus induction in mouse bone marrow erythroctes at the same dose level. Mutation Research 583, 158-167.


Kirkland, D., and Fowler, P. (2010). Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells at concentrations exceeding 1mM including retest of compounds of concern. Mutagenesis 25, 539-553.


Kirkland, D.J., Aardema, M., Banduhn, N., Carmichael, P., Fautz, R., Meunier, J.R., and Pfluhler, S. (2007c). In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results. Mutagenesis 22, 161-175.


GLOSSARY

**Adduct**: A chemical grouping which is covalently bound to a large molecule such as DNA or protein.

**Alkylating agents**: Chemicals which leave an alkyl group covalently bound to biologically important molecules such as proteins and nucleic acids (see adduct). Many alkylating agents are mutagenic, carcinogenic and immunosuppressive.

**Ames test**: *In vitro* assay for bacterial gene mutations using strains of *Salmonella typhimurium* developed by Ames and his colleagues.

**Aneugenic**: Inducing aneuploidy (qv).

**Aneuploidy**: The circumstances in which the total number of chromosomes within a cell is not an exact multiple of the normal haploid (see 'polyploidy') number. Chromosomes may be lost or gained during cell division.

**Apoptosis**: A form of active cell death resulting in fragmentation of the cell into membrane-bound fragments (apoptotic bodies). These are usually rapidly removed *in vivo* by engulfment by phagocytic cells. Apoptosis can occur normally during development, but is often triggered by toxic stimuli.

**Cancer**: Synonym for a malignant neoplasm – that is, a tumour (qv) that grows progressively, invades local tissues and spreads to distant sites (see also tumour).

**Carcinogenesis**: The origin, causation and development of tumours (qv). The term applies to benign as well as malignant neoplasms and not just to carcinomas.

**Carcinogenicity bioassay**: Tests carried out in laboratory animals, usually rats and mice, to determine whether a substance is carcinogenic. The test material is given throughout life to groups of animals at different dose levels.

**Carcinogens**: The causal agents which induce tumours. They include external factors (chemicals, physical agents, viruses) and internal factors such as hormones. Chemical carcinogens are structurally diverse and include naturally-occurring substances as well as synthetic compounds. An important distinction can be drawn between genotoxic (qv) carcinogens which have been shown to react with and mutate DNA, and non-genotoxic carcinogens which act through other mechanisms. The activity of genotoxic carcinogens can often be predicted from their chemical structure - either of the parent compound or of active metabolites (qv). Most chemical carcinogens exert their effects after prolonged exposure, show a dose-response
relationship and tend to act on a limited range of susceptible target tissues. Carcinogens are sometimes species or sex-specific and the term should be qualified by the appropriate descriptive adjectives to aid clarity. Several different chemical and other carcinogens may interact, and constitutional factors (genetic susceptibility, hormonal status) may also contribute, emphasising the multifactorial nature of the carcinogenic process.

**Chromosomal aberrations:** Collective term of particular types of chromosome damage induced after exposure to exogenous chemical or physical agents which damage the DNA. (see clastogen).

**Chromosome:** In simple prokaryotic organisms, such as bacteria and most viruses, the chromosome consists of a single circular molecule of DNA containing the entire genetic material of the cell. In eukaryotic cells, the chromosomes are thread-like structures, composed mainly of DNA and protein, which are present within the nuclei of every cell. They occur in pairs, the numbers varying from one to more than 100 per nucleus in different species. Normal somatic cells in humans have 23 pairs of chromosomes, each consisting of linear sequences of DNA which are known as genes.

**Clastogen:** An agent that produces chromosome breaks and other structural aberrations such as translocations. Clastogens may be viruses or physical agents as well as chemicals. Clastogenic events play an important part in the development of some tumours.

**Cytogenetic:** Concerning chromosomes, their origin, structure and function.

**Cytochrome P450 (CYP):** An extensive family of haem-containing proteins involved in enzymic oxidation of a wide range of endogenous and xenobiotic (qv) substances and their conversion to forms that may be more easily excreted. In some cases the metabolites produced may be reactive and may have increased toxicity. In other cases the substances may be natural precursors of hormones (e.g. steroids).

**DNA Strand Breakage:** A break in double-stranded DNA in which one or both of the two strands have been cleaved; both strands have not separated from each other.

**DNA Strand Break Assay (Comet assay):** Alkaline treatment converts certain types of DNA lesions into strand breaks that can be detected by the alkaline elution technique or by measuring migration rate through a filter, or by the single gel electrophoresis or Comet assay in which cells embedded in a thin layer of gel on a microscope slides are subjected to electric current causing shorter pieces of DNA to
migrate out of the nucleus into a Comet tail. The extent of DNA migration is measured visually under the microscope on stained cells.

**Erythrocyte**: red blood cell; corpuscle; one of the formed cells in peripheral blood. Normally, in humans, the mature form is a non-nucleated, yellowish, biconcave disk, containing haemoglobin and transporting oxygen. Normochromic erythrocyte; one of normal colour with a normal concentration of haemoglobin. Polychromatlic erythrocyte; one that, on staining, shows shades of blue combined with tinges of pink indicative of an immature erythrocyte.

**Eukaryotes**: A class of organisms, which in contrast to prokaryotes (e.g. bacteria), comprise cells which have a nucleus in which DNA is organised into characteristic sets of chromosomes. This includes all plants and fungi except the blue-green algae and all animals.

**Fluorescent in situ hybridization (FISH)** A technique in which a chemically modified DNA (or RNA) probe is hybridized with target DNA, usually present as a chromosome preparation on a microscopic slide. The chemical modification can be visualized using a fluorescent microscope either directly when the modification involves use of a fluorescent dye or indirectly with the use of a fluorescently labelled affinity reagent (e.g. antibody or avidin). Depending upon the type of probe used, this approach can be used to precisely map genes to a specific region of a chromosome in a prepared karyotype, enumerate chromosomes, or detect chromosomal deletions, translocations, or gene amplifications in cancer cells.

**Gametogenesis** is a process by which diploid or haploid precursor cells undergo cell division and differentiation to form mature haploid gametes. Depending on the biological life cycle of the organism, gametogenesis occurs by meiotic division of diploid gametocytes into various gametes or by mitotic division of haploid gametogenous cells.

**Genome**: All the genetic material in the chromosomes of a particular organism; its size is generally given as its total number of base pairs.

**Genotoxic**: The ability of a substance to cause DNA damage, either directly or after metabolic activation (see also carcinogens).

**Genotype**: The particular genetic pattern seen in the DNA of an individual. 'Genotype' is usually used to refer to the particular pair of alleles that an individual possesses at a certain location in the genome. Compare this with phenotype.
**Germ cell:** A biological cell that gives rise to the gametes of an organism that reproduces sexually. The cells undergo mitotic and meiotic cell division in the gonads followed by cellular differentiation into mature gametes, either oocytes or sperm.

**Heritable translocation test** A test that detects heritable structural chromosome changes (i.e. translocations) in mammalian germ cells as recovered in first-generation progeny.

**Historical negative control data:** In the context of the COM guidance on genotoxicity testing, this term refers to information on the background genotoxicity or mutagenicity data for a particular assay from a particular laboratory. Historical control data should be reported as the mean and confidence intervals for the genotoxicity or mutagenicity indices investigated.

**In vitro chromosomal aberration assay:** An assay where cultured cell lines or human lymphocytes are incubated with test substance. At a predetermined time, cells are arrested in metaphase, harvested and stained, and the metaphase spreads are then analysed microscopically for the presence of chromosome aberrations.

**Kinetochore** is the protein structure which is present on chromosomes where the spindle fibers attach during division to pull the chromosomes apart. The kinetochore forms in eukaryotes and assembles on the centromere and links the chromosome to microtubule polymers from the mitotic spindle during mitosis and meiosis. The kinetochore contains two regions: an inner kinetochore, which is tightly associated with the centromere DNA; and an outer kinetochore, which interacts with microtubules.

**Kinetochore staining** An immunochemical technique used to detect the presence of centromeric kinetochore proteins in micronuclei and to identify the origin of micronuclei. In all but a few cases, the presence of kinetochore in a micronucleus indicates that it was formed by loss of an entire chromosome, whereas a micronucleus that lacks a kinetochore originated from an acentric chromosome fragment.

**Maximum Tolerated Dose:** The highest dose of a substance that can be given without causing serious weight loss (>10%) or other signs of toxicity.

**Metabolic activation:** Metabolism of a compound leading to an increase in its activity, whether beneficial (e.g. activation of a pro-drug) or deleterious (e.g. activation to a toxic metabolite).
**Metabolic activation system:** A cell-free preparation (e.g. from the livers of rats pretreated with an inducing agent added to *in vitro* tests to mimic the metabolic activation typical of mammals.

**Metabolism:** Chemical modification of a compound by enzymes within the body, for example by reactions such as hydroxylation (see cytochrome P450), epoxidation or conjugation. Metabolism may result in activation, inactivation, accumulation or excretion of the compound.

**Metabolite:** Product formed by metabolism of a compound.

**Micronuclei:** Isolated or broken chromosome fragments which are not expelled when the nucleus is lost during cell division, but remain in the body of the cell forming micronuclei. Centromere positive micronuclei contain DNA and/or protein material derived from the centromere. The presence of centromere positive micronuclei following exposure to chemicals *in vitro* or *in vivo* can be used to evaluate the aneugenic (qv) potential of chemicals.

**Micronucleus test:** See Micronuclei.

**Mitogen:** A stimulus which provokes cell division in somatic cells.

**Mitosis:** The type of cell division which occurs in somatic cells when they proliferate. Each daughter cell has the same complement of chromosomes as the parent cell.

**Mode of Genotoxic Action (MoGA):** The mode of action of genotoxicant refers to the underlying events involved in the process whereby the chemical induces genotoxic effects. In order for a specific mode of action to be supported there needs to be evidence from robust mechanistic data to establish a biologically plausible explanation. Mode of genotoxic action should be distinguished from the term mechanism of action. The latter relates to having sufficient understanding of the molecular basis of the chemical genotoxicity to establish causality. Thus mechanism of action is at the other end of a continuum from little or no evidence of mode of genotoxic action to scientific proof of mechanism of action.

**Mouse lymphoma assay:** An *in vitro* assay for gene mutation in mammalian cells using a mouse lymphoma cell line L5178Y, which is heterozygous for the gene (carries only one functional gene rather than a pair) for the enzyme thymidine kinase (TK<sup>+</sup>). Mutation of that single gene is measured by resistance to toxic trifluorothymidine. Mutant cells produce two forms of colony - large, which represent mutations within the gene and small, which represent large genetic changes in the chromosome such as chromosome aberrations. Thus this assay can provide
additional information about the type of mutation which has occurred if colony size is scored.

**Mutation**: A permanent change in the amount or structure of the genetic material in an organism or cell, which can result in a change in phenotypic characteristics. The alteration may involve a single gene, a block of genes, or a whole chromosome. Mutations involving single genes may be a consequence of effects on single DNA bases (point mutations) or of large changes, including deletions, within the gene. Changes involving whole chromosomes may be numerical or structural. A mutation in the germ cells of sexually reproducing organisms may be transmitted to the offspring, whereas a mutation that occurs in somatic cells may be transferred only to descendent daughter cells.

**Mutagenic end-points**: these comprise of three levels of genetic change, namely gene mutation, clastogenicity and aneuploidy

**No observable effect concentration (NOEC)**: the highest administered concentration at which no adverse effect or specific genotoxic effect is seen

**Phenotype**: The observable physical, biochemical and physiological characteristics of a cell, tissue, organ or individual, as determined by its genotype and the environment in which it develops.

**Polyploidy**: Numerical deviation of the modal number of chromosomes in a cell, with approximately whole multiples of the haploid number. Endoreduplication is a morphological form of polypoidy in which chromosome pairs are associated at metaphase as diplochromosomes.

**32P-postlabelling**: A sensitive experimental method designed to measure low levels of DNA adducts induced by chemical treatment.

**Prokaryotes**: The simplest living organisms namely viruses, bacteria and some blue green algae. The genetic material in bacteria is arranged into one chromosomal complex consisting of a single circular molecule of DNA (or RNA in some viruses). They lack an organised nucleus. Mitosis and meiosis do not occur, although nucleotide polymerisation replication takes place and division and multiplication follow.

**Recombination**: Breakage of DNA structure with balanced or unbalanced rejoining of DNA

**S9**: metabolic activation system comprising of the post-mitochondrial supernatant (S9) from the homogenised livers of rats treated with P450 dependent drug-
metabolizing enzyme inducers such as Arochlor 1254 or phenobarbitone/β-naphthoflavone. S9 is combined with a mix of co-factors which optimize the activity of the mixed function oxidases and form a NADPH generating system which has the capacity to metabolise chemicals in vitro.

**Sensitivity:** In the context of the COM guidance on a strategy for genotoxicity testing, the correct identification of rodent carcinogens or in vivo genotoxins using genotoxicity (mutagenicity) assays based on a defined set of carcinogenicity data (e.g. Gold Carcinogenicity Potency database)

**Screening test:** High-Throughput procedures designed to provide rapid information on toxicological end points for a large number of compounds

**Specificity:** In the context of the COM guidance on a strategy for genotoxicity testing, the correct prediction of non-carcinogens as assessed in rodent carcinogenicity bioassays using genotoxicity (mutagenicity) assays based on a defined set of carcinogenicity data (e.g. Gold Carcinogenicity Potency database).

**Specific locus test:** A technique used to detect recessive induced mutations in diploid organisms; a strain that carries several known recessive mutants in a homozygous condition is crossed with a non mutant strain that has been treated to induce mutations in its germ cells; induced recessive mutations allelic with those of the test strain will be expressed in the progeny.

**Spindle apparatus:** In cell biology, the spindle apparatus is the structure that separates the chromosomes into the daughter cells during cell division. It is part of the cytoskeleton in eukaryotic cells. It is also referred to as the mitotic spindle during mitosis and the meiotic spindle during meiosis.

**Structure Activity Relationships:** the relationship between chemical structure and genotoxic effect based on predictions using computerised models (also Quantitative Structure Activity Relationships)

**Test substance:** A chemical element and its compounds in the natural state or obtained by any manufacturing process, including any additive necessary to preserve its stability and any impurity deriving from the process used, but excluding any solvent which may be separated without affecting the stability of the substance or changing its composition.

**Threshold:** Dose or exposure concentration below which an effect is not expected.

**Topoisomerases:** Enzymes which catalyze and guide the unknottting of DNA by creating transient breaks in the DNA using a conserved tyrosine as the catalytic
residue. In so-called circular DNA, in which double helical DNA is bent around and joined in a circle, the two strands are topologically linked, or knotted. Topoisomerase I solves the problem caused by tension generated by winding/unwinding of DNA. It wraps around DNA and makes a cut permitting the helix to spin. Once DNA is relaxed, topoisomerase reconnects broken strands.

**Toxicogenomics**: A new scientific subdiscipline that combines the emerging technologies of genomics and bioinformatics to identify and characterise mechanisms of action of known and suspected toxicants. Currently, the premier toxicogenomic tools are the DNA microarray and the DNA chip, which are used for the simultaneous monitoring of expression levels of hundreds to thousands of genes.

**Toxicokinetics**: The description of the fate of chemicals in the body, including a mathematical account of their absorption, distribution, metabolism and excretion. (see pharmacokinetics)

**Transgenic**: Genetically modified to contain genetic material from another species (see also genetically modified organism).

**Transgenic rodent gene mutation models**: Animals which have extra (exogenous) fragments of DNA incorporated into their genomes. This includes transgenic mice containing reporter genes to assess *in-vivo* mutagenicity in recoverable bacterial gene (*lacZ* or *lac I*). DNA can be isolated from a wide range of tissues following exposure to a test substance and the genes assessed for induced mutations.

**Translation**: In molecular biology, the process during which the information in mRNA molecules is used to construct proteins.

**Tumour (Synonym - neoplasm)**: A mass of abnormal, disorganised cells, arising from pre-existing tissue, which are characterised by excessive and uncoordinated proliferation and by abnormal differentiation. **Benign** tumours show a close morphological resemblance to their tissue of origin; grow in a slow expansile fashion; and form circumscribed and (usually) encapsulated masses. They may stop growing and they may regress. Benign tumours do not infiltrate through local tissues and they do not metastasise. They are rarely fatal. **Malignant tumours** (synonym - cancer) resemble their parent tissues less closely and are composed of increasingly abnormal cells in terms of their form and function. Well differentiated examples still retain recognisable features of their tissue of origin but these characteristics are progressively lost in moderately and poorly differentiated malignancies: undifferentiated or anaplastic tumours are composed of cells which resemble no known normal tissue. Most malignant tumours grow rapidly, spread progressively...
through adjacent tissues and metastasise to distant sites. Tumours are conventionally classified according to the anatomical site of the primary tumour and its microscopical appearance, rather than by cause.

**Unscheduled DNA Synthesis (UDS):** DNA synthesis that occurs at some stage in the cell cycle other than the S period (the normal or 'scheduled' DNA synthesis period), in response to DNA damage. It is usually associated with DNA repair.

**Weight of Evidence** A quantitative ranking of evidence, or the qualitative appraisal of many different forms of evidence (e.g. toxicological or genotoxicity data) to arrive at a conclusion regarding potential hazard (such as mutagenicity).
Figure 1: Overview of Strategy for testing chemical substances for genotoxicity

Stage 0:
Structure Activity Relationships (SAR), screening tests and physico-chemical properties (of substances and impurities)

Stage 1:
1. Bacterial gene mutation test (Ames test)
2. Clastogenicity and aneugenicity (in vitro micronucleus test)

NEGATIVE results in all tests
EQUIVOCAL result in any test
POSITIVE result in any test

NEGATIVE after full assessment

Stage 2: Consider rationale for in vivo study selection; may include:
- Mutagenic endpoints identified in Stage 1 in vitro tests
- Tumour target tissues in carcinogenicity studies
- Potential for germ cell genotoxicity
- Negative in Stage 1 but where exposure is high, or moderate and prolonged
- Site of contact tissues

Undertake one or more of the following recommended assays:
1. Micronucleus assay
2. Transgenic rodent mutation assay
3. Comet assay

Substance is not mutagenic
Insufficient evidence to assess the mutagenicity of the substance
Review available data and make pragmatic conclusions based on weight of evidence

POSITIVE: if data are robust consider substance to be in vivo somatic cell mutagen and possible germ cell mutagen is considered to be mutagenic.
Figure 2: Screening (Stage 0) and in vitro tests (Stage 1)

Stage 0:
Structure Activity Relationships (SAR), screening tests, and physico-chemical properties (substance/impurities)

Stage 1 Core Tests:
1. Bacterial gene mutation (Ames test)
2. Clastogenicity and aneugenicity (in vitro micronucleus test)

NEGATIVE results in all Stage 1 tests
EQUIVOCAL result in any Stage 1 test
POSITIVE result in any Stage 1 test

Consider other factors that indicate additional evaluation is required:
- Structural alerts,
- Results of other tests (e.g. rodent tumours)

Consider:
- Reproducibility
- Historical control data
- Mode of Genotoxic Action (MoGA)
- Results of stage 0
- Additional in vitro tests (e.g. Mammalian cell mutation, mammalian cytogenetics, Comet assay, or human reconstituted skin)

Substance is not mutagenic
Insufficient evidence to assess the mutagenicity of the substance
Substance should be considered to be an in vitro mutagen.

If high, or moderate and prolonged exposure, consider proceeding to Stage 2 only where in vivo testing is permitted*

Proceed to Stage 2 only where in vivo testing is permitted*

* In situations where in vivo testing is prohibited, further in vitro testing should be considered
Figure 3: Testing for *in vivo* mutagenic potential (Stage 2)

**Stage 2:**
Rationale for *in vivo* study selection may include:
- Mutagenic endpoints identified in Stage 1 *in vitro* tests
- Tumour target tissues in carcinogenicity studies
- Potential for germ cell genotoxicity
- Negative Stage 1 but where exposure is high, or moderate and prolonged
- Site of contact tissues

Devise and justify initial testing strategy which may incorporate one of the following recommended assays:
1. Micronucleus assay
2. Transgenic rodent mutation assay
3. Comet Assay

**NEGATIVE results in all appropriate Stage 2 tests**
- Substance is not mutagenic *in vivo*

**EQUIVOCAL result in any Stage 2 test**
- Insufficient evidence to assess the mutagenicity of the substance
- Review available data and make pragmatic conclusions based on weight of evidence

**POSITIVE result in any Stage 2 test**
- Substance should be considered to be an *in vivo* somatic cell mutagen and possible germ cell mutagen.

Consider:
- Reproducibility
- Historical control data
- Mode of Genotoxic Action (MoGA)
- Results of stage 0, 1 & 2 tests.
- Toxicokinetic and metabolic information.
- If further *in vitro* or *in vivo* testing is warranted. Select appropriate tests on a case-by-case basis: (e.g. DNA adducts)

Consider:
- Historical control data
- Mode of Genotoxic Action (MoGA)
- Results of other Stage 0, 1 & 2 tests
- Misleading positive results